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Background: Due to the rise in antimicrobial resistance and the challenges accompanied 
by conventional antibiotic dosage forms, there is a need for developing drug delivery 
systems that enhance, protect and potentiate the current antibiotics in the market. 
Furthermore, natural derivatives from plants have proven to be potent antimicrobial 
agents. Therefore, their combination with antibiotics could be effective in overcoming 
antimicrobial resistance.  
Aim: The aim of this study was to co-deliver vancomycin and 18β-glycyrrhetinic acid via 
pH-responsive lipid-polymer hybrid nanoparticles (VCM-GAPAH-LPHNPs) formulated 
from polyallylamine and oleic acid (OA) and to explore its potential for enhanced activity 
and targeted delivery.  
Methods: Molecular dynamics and stability studies were used to determine the stability 
of the oil and water phases independently as well as VCM-GAPAH-LPHNPs as a 
complex. VCM-GAPAH-LPHNPs were prepared using the micro-emulsion technique. 
The size, polydispersity index and zeta potential of VCM-GAPAH-LPHNPs were 
determined using the dynamic light scattering technique. Transmission electron 
microscopy analysis was conducted to determine the morphology of VCM-GAPAH-
LPHNPs. The entrapment efficiency and drug loading were determined using the 
ultrafiltration method. Differential scanning calorimetry was used to determine the 
thermal profiles of VCM-GAPAH-LPHNPs and its components. In vitro drug release 
studies were performed using the dialysis bag technique. Drug release kinetics were 
analysed using the DDSolver program. Cytotoxicity of VCM-GAPAH-LPHNPs were 
determined using the MTT assay. Haemolysis of VCM-GAPAH-LPHNPs were 
performed at different concentrations using sheep blood. In vitro antibacterial activity of 
VCM-GAPAH-LPHNPs were determined against SA and methicillin-resistant 
Staphylococcus aureus (MRSA) at pH 6 and 7.4. Time killing assay was performed using 
the plate colony count method. MRSA biofilm study was performed using the crystal 
violet assay.  
Results: Molecular dynamics indicated VCM-GAPAH-LPHNPs to be stable. VCM-
GAPAH-LPHNPs were successfully prepared using the micro-emulsion technique. 




efficiency were found to be 198.4 ± 0.302 nm, 0.255 ± 0.003, - 3.8 ± 0.335 mV and 69.46 
± 2.52 % respectively. Thermal profiles of lyophilized VCM-GAPAH-LPHNPs showed 
transformation from crystallization to amorphous form. In vitro drug release studies 
revealed that VCM-GAPAH-LPHNPs released 60% of VCM after 24 h whereas bare 
VCM released 90% of VCM after 24 h hence VCM-GAPAH-LPHNPs showed sustained 
drug release compared to bare VCM. At pH 6 VCM-GAPAH-LPHNPs released 82% of 
VCM after 24 h whereas at pH 7.4 VCM-GAPAH-LPHNPs released 60% of VCM after 
24 h indicating VCM-GAPAH-LPHNPs had a faster drug release at pH 6 compared to 
pH 7.4. The Weibull model was considered the best fit model for VCM-GAPAH-
LPHNPs. The MTT assay revealed 75% > cell viability which indicated VCM-GAPAH-
LPHNPs to be non-cytotoxic. At 0.5 mg/ml VCM-GAPAH-LPHNPs showed < 1% 
haemolysis. Stability studies at 4 °C and room temperature indicated VCM-GAPAH-
LPHNPs to be stable. In vitro antibacterial activity against MRSA treated with VCM-
GAPAH-LPHNPs demonstrated a 16-fold lower minimum inhibitory concentration than 
bare VCM at acidic conditions. The time-killing assay study at 12 h revealed that VCM-
GAPAH-LPHNPs eliminated 100% of MRSA cells whereas bare VCM eliminated 55% 
of MRSA cells. The crystal violet assay analysis revealed VCM-GAPAH-LPHNPs ability 
to eliminate MRSA biofilms.  
Conclusion: VCM-GAPAH-LPHNPs could effectively treat MRSA infections at a faster 
rate as compared to bare VCM. Therefore, this novel pH-responsive LPHNPs may serve 
as a promising nanocarrier for enhancing antibiotic delivery and antibacterial activity. 
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Chapter One - Introduction 
 
1.1 Introduction  
This chapter provides a brief background of the study including the crisis of infectious diseases, 
limitations of conventional antibiotic therapy and the threat of a post-antibiotic era. It further 
discusses the advantages of pH-responsive nanodrug delivery systems and their role in 
combatting antibiotic resistance. This is followed by the aims, novelty and significance of the 
study and concludes with an overview of the dissertation. 
1.2 Background  
Infectious diseases, particularly bacterial infections are considered one of the primary causes 
of morbidity and mortality worldwide, despite influential research advancements (1). Recent 
data indicates that by 2050 there will be 10 million annual deaths caused by bacterial infections 
(2). Antibiotics are designed to inhibit or stop bacterial infections and have revolutionized the 
treatment of infectious diseases via their bacteriostatic and bactericidal effects (3). However, 
conventional antibiotic dosage forms need to be administered regularly for a sustained period 
to maintain adequate concentrations at target sites of infection (4) and to avoid persistent 
infections due to the development of antibiotic resistance (5). Furthermore, the high dose of 
antibiotics being administered leads to harmful side effects (6, 7), poor pharmacokinetic 
properties (6), a burden on the healthcare sector and treatment costs and poor patient 
compliance (8).  
Such disadvantages, compounded by incorrect usage and exploitation of antibiotics (1, 9) have 
led to an antibiotic-resistant era (9). Antibiotic-resistant and multidrug-resistant (MDR) 
bacteria such as MRSA pose a greater threat to humankind than ever imagined (10). MRSA is 
a common pathogen present in community and hospital-acquired infections (11) and 
contributes to the development of sepsis (12, 13), peritonitis (13), endocarditis and bacteraemia 
(14). The prolonged discovery and advancement of novel antibiotics, as well as high production 
costs, emphasize the need to strategically introduce new dimensions to suppress the rapid 
increase of bacterial resistance to antibiotics and limitations of conventional antibiotics (15, 
16). Nanoengineered antibiotic delivery systems have been reported as a promising approach 
to overcome the restrictions of conventional antibiotics and resistance of bacteria (17, 18). 
Nano drug delivery systems (NDDS) are defined as biocompatible, nanosized materials having 




conventional dosage forms of antibiotics, these include targeted antibiotic delivery to infection 
sites, enhanced localisation of the antibiotic within target tissues (20), improved 
pharmaceutical stability (21), improved antibiotic solubility, improved cellular absorption, 
sustained antibiotic release (22), improved patient compliance and reduced side effects (23). 
Some nanosystems that have been explored as NDDS for antibiotics include liposomes (24), 
polymeric nanoparticles (PNPs) (25), lipid polymer hybrid nanoparticles (LPHNPs) (26), 
dendrimers (27), solid lipid nanoparticles (SLNs) (28) and micelles (29). Of these NDDS, lipid-
polymer hybrid nanoparticles (LPHNPs) have shown major potential as antibiotic nanocarriers 
with enhanced antibacterial efficacy. They were first proposed in the late 1970s as a promising 
antibiotic delivery system (30) and are composed of biocompatible/biodegradable polymers, 
whereby the antibiotic is solubilized, encased or anchored to the outer surface of nanoparticles 
(31). There are many advantages of LPHNPs, which include improved concentration of 
antibiotics at target infection sites thus improving drug safety (32), protection of the antibiotic 
(23), reduced premature drug release before arrival at the infection site, controlled and 
sustained antibiotic release, improved cell penetration and solubility (33), cost-effective 
upscaled production using controlled polymerization techniques (34), improved stability of 
volatile chemical substances (35), antimicrobial properties (36) and biocompatibility with 
tissues (31-34, 36). Recently LPHNPs have been employed to deliver the messenger RNA from 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for creation of the vaccine 
against the disease (37). Therefore, LPHNPs are efficient and effective drug delivery 
nanosystems (38).  
Spurred by the advancements in pharmaceutical chemistry and drug delivery, stimuli-
responsive NDDS are of recent interest. Researchers are committed to developing stimuli-
responsive nanosystems (39) to heighten the efficiency and effectiveness of NDDS. Stimuli-
responsive antibiotic delivery systems are designed for optimal response to endogenous stimuli 
(i.e., enzymes, redox potential, ionic microenvironment and pH levels) and exogenous stimuli 
(i.e., temperature, ultrasound, electric, mechanical, light and magnetic fields) at an infection 
site, allowing targeted antibiotic release, improved antibiotic accumulation as well as enhanced 
bioavailability at the target site (39, 40). Among these stimuli, pH-responsive NDDS have 
become extremely popular in the literature. The significance of pH-responsive NDDS lies in 
their ability to deliver antibiotics when minor pH changes according to the pathophysiology 
properties of the disease are presented, resulting in enhanced therapeutic efficacy and patient 




present with changes towards an acidic pH, which varies from the physiological pH of 7.4 (41, 
42). Effective pH-responsive nanosystems such as pH-responsive liposomes (24), polymeric 
nanoparticles (30) and micelles (29) aim at targeting acidic pH conditions (42). pH-sensitive 
NDDS have been reported for the delivery of anti-cancer (41-43) and antibacterial (44-46) 
agents at targeted infection sites. However, limited research has been done on pH-sensitive 
nano drug delivery to bacterial infection sites, specifically that of MRSA, which has the 
potential to massively influence infectious disease treatment by improved and targeted drug 
delivery to acidic infection sites and curb the limitations of conventional antibiotics (47, 48).  
Currently, LPHNPs are being employed to efficiently deliver drugs, making them promising 
nanosystems (49). LPHNPs overcome the above-mentioned problems of conventional 
antibiotic dosage forms and antimicrobial resistance by combining the structural components 
of PNPs and liposomes (50). LPHNPs are core-shell self-assembled drug delivery systems 
fabricated from a hydrophobic lipid core and a polymeric matrix (51). The biofunctional 
properties of LPHNPs allow the formulation of a system that is stimuli-responsive (52). This 
is attained by focusing on the properties of the nanoparticle matrix in order to establish targeted 
drug delivery and enhanced antibacterial activity (53). The development in the field of 
nanotherapeutics and material sciences has stimulated the advancement of pH-sensitive 
nanosystems for effective and efficient antibiotic delivery (54, 55). Several pH-responsive 
LPHNPs have been reported for antibacterial and anticancer studies (56-58). However, there is 
limited literature on employing pH-sensitive LPHNPs for antibiotic delivery. Therefore, using 
this approach, systems can be fabricated to have programmable destabilization and drug release 
due to pH changes that correspond with bacterial infection sites (58, 59). 
The bioactive phytochemical composites found in plants and natural plant derivatives possess 
a broad spectrum of activity, 18β-glycyrrhetinic acid (GA) is such a natural derivative (60). 
GA is the hydrolyzed product of glycyrrhizic acid which is derived from the Glycyrrhiza glabra 
(liquorice) plant (61).This biologically active compound has been reported to have anti-allergic 
(62), antibacterial, antiviral, antitumor and anti-inflammatory characteristics (63, 64). Due to 
the antibacterial activity of GA, it can be explored by co-delivery with antibacterial drugs in 
the market for synergistic action (63, 65). 
Literature reports indicate the combinational therapy of antibiotics in the market and natural 
plant derivatives that have shown to improve antibacterial activity (66). However, there are no 




infections. Therefore, the combined delivery of GA and antibiotics can further be explored by 
co-loading in a stimuli-responsive nanosystem for targeted and enhanced antimicrobial activity 
(67). Such a system will also provide scientific advancement to the field of pharmaceutics. 
There are numerous reports of GA being co-delivered with cancer and inflammatory drugs in 
nanosystems for the treatment of cancer diseases (68-70). However, from our search of the 
literature, such a formulation for co-delivery of GA and antibiotics has not been done before. 
Thus, in this study, we propose the co-delivery of GA and VCM via polyallylamine 
hydrochloride (PAH) LPHNPs for enhanced and targeted antibiotic delivery. The pH-
responsive LPHNPs matrix consists of PAH and oleic acid (OA). We envisage the pH-response 
will stem from the ionisable carboxylic acid groups of OA and primary amino groups of PAH. 
At a basic pH, carboxylic acid groups deprotonate and form electrostatic bonds with the anime 
groups of PAH. Thus, the system will have an overall negative charge. Consequently, at acidic 
conditions, both the amine and carboxylic groups will protonate, the carboxylic group will have 
a slightly positive charge that will repel the highly positive charge of PAH amine groups thus 
LPHNPs charge shift from negative to positive charge, followed by cleavage of the electrostatic 
bond, ultimately resulting in swelling of LPHNPs and faster release of drugs. Additionally, the 
positive charge of PAH polymer may promote attachment to the negatively charged bacterial 
cell wall, thus enhancing antibacterial activity. Such a system to the best of our knowledge has 
not been reported before. Moreover, LPHNPs can encapsulate both hydrophilic and 
hydrophobic drugs, in this system GA is co-delivered with VCM. Such a strategy has not been 
reported before for delivery of antibiotics with bioactive plant by-products. Therefore, this 
study will report novel multifunctional LPHNPs that are pH- responsive for co-delivery of GA 
and VCM.  
1.3 Problem statement 
Globally, bacterial infections are a significant problem in the healthcare sector. This is due to 
the several disadvantages of current treatment regimes, including conventional dosage forms 
of current antibiotics, low drug concentrations at infection sites, frequent high dosages, poor 
pharmacokinetics, poor patient compliance and adverse side effects. Such restrictions have 
resulted in the birth of an antibiotic-resistant era that is associated with a rise in mortality and 
morbidity rates. The advancement of new antimicrobials is deteriorating, urging the design and 
discovery of novel approaches to improve current antibiotic treatment. The establishment of 




infection sites, thereby enhancing antibiotic therapy. Ultimately, the development of pH-
responsive co-delivery systems is required to overcome the challenges associated with current 
antibiotic dosage forms and antimicrobial resistance. 
1.4 Hypothesis 
We hypothesize that the co-delivery of GA and VCM via pH-responsive PAH-LPHNPs 
formulation can enhance its antibacterial activity.  
1.5 Aims and objectives 
The aim of this study was to identify the potential of the co-delivery of GA and VCM via pH-
responsive PAH lipid-polymer hybrid nanoparticles (GAPAH-LPHNPs) for enhancing 
antibacterial activity. 
The objectives of the study were: 
1. To synthesize novel pH-responsive GAPAH lipid-polymer hybrid nanoformulation 
encapsulating VCM and GA. 
2. To optimize and characterize VCM-GAPAH-LPHNPs in terms of particle size, 
polydispersity index (PDI), zeta potential (ZP), pH-responsiveness, morphology, entrapment 
efficiency and in vitro drug release. 
3. To assess in vitro antibacterial activity of VCM-GAPAH-LPHNPs against SA and MRSA. 
4. To identify time-killing kinetics against MRSA. 
5. To perform crystal violet assay analysis against MRSA biofilms. 
1.6 Novelty of the study 
The research conducted in this study is novel for the following reasons: 
• This study reports for the first time LPHNPs coined from PAH and OA.  
• This study reports the synthesis and characterization of multifunctional LPHNPs 
designed for pH-responsive co-delivery of VCM and GA, which have not been 
previously reported in the literature.  
• This work also reports for the first time the co-delivery of an antibiotic and bioactive 





1.7 Significance of the study 
These reported pH-responsive LPHNPs for co-delivery of GA and VCM present a novel and 
promising avenue for targeting acidic infection sites, thus enhancing drug localisation within 
target tissues, reducing concentration of the dosage needed for ideal treatment, improving 
antibiotic properties and preventing the occurrence of bacterial resistance. Ultimately, this 
results in minimal side effects and improves patient adherence to treatment. The potential 
significance of this study is mentioned below:  
Advanced nanomedicine 
This study proposes the novel pH-responsive LPHNPs for co-delivery of an antibiotic and 
natural compound formulation as a medicine. This nanomaterial and medication can play a role 
in pharmaceutical companies in the development of novel pH-responsive drug delivery 
vehicles that could be more effective than conventional antibiotics.  
 
Advanced patient and disease treatment 
This novel nanocarrier has the potential to advance bacterial infection treatment by allowing 
targeted and controlled release at infection sites, enhancing drug localization and 
bioavailability at acidic infection site thus, contributing to the improvement of antibacterial 
properties, reduction of dosage frequency and minimal side effects, which ultimately improves 
patient adherence and defeats threats against antibacterial resistance. 
Creating novel scientific knowledge 
This study can identify new scientific advancements in the preparation and characterization of 
the combinational delivery of antibiotics and natural plant compounds of pH-responsive lipid-
polymer hybrid nanoparticles and their potential in the world of nanotechnology. Thereby 
combinational delivery may contribute to the synthesis of effective and novel nano-drug 
delivery systems and enhance their capability within pharmaceutical applications. 
Stimulation of advanced research 
This study can provide novel avenues for the preparation and characterization of pH-responsive 
LPHNPs for the co-delivery of antibiotics and natural compounds for their potential 
applications in pH-responsive nanosystems formulation for several antibiotic classes and other 





1.8 Overview of the dissertation 
The research is presented in the following chapters: 
Chapter One - Introduction:  
This chapter provides a concise background of the study including the burden of infectious 
diseases on the healthcare sector, limitations of conventional antibiotic therapy and the threat 
of a post-antibiotic era. It further discusses the advantages of pH-responsive nanodrug delivery 
systems and their role in combatting antibiotic resistance. This is followed by the aims, novelty 
and significance of the study and concludes with an overview of the dissertation. 
Chapter Two - Literature Review: 
This chapter provides an overview of the burden of ID on the healthcare system and antibiotic 
therapy limitations that have led to the development of bacterial resistance. It also provides an 
overview of lipid-polymer hybrid nanoparticle characteristics, preparation and characterization 
technique, outlines the use of pH-responsive NDDS as a strategy to influence the treatment of 
infectious diseases and concludes with an overview of vancomycin as a model drug. 
 
Chapter Three - Submitted manuscript: 
This chapter is a first author article that was submitted to an international ISI journal i.e. 
International Journal of Pharmaceutics (Impact factor of 4.845). The chapter is presented in the 
required format of the journal. It describes the synthesis of novel VCM-GAPAH lipid-polymer 
hybrid nanoparticles. It also highlights the in vitro cytotoxicity evaluation, haemolytic study, 
formulation of the pH-responsive LPHNPs (VCM-GAPAH-LPHNPs) for targeted delivery of 
VCM and characterization of its physical and antibacterial properties via in silico studies and 





Chapter Four – Conclusions: 
This chapter describes the conclusions reached in achieving the study aim, objectives, outlines 
the significance of the findings and provides future recommendations for further scientific 
research into antibiotic and natural compound co-delivery of pH-responsive lipid-polymer 














1. Kalhapure RS, Suleman N, Mocktar C, Seedat N, Govender T. Nanoengineered drug 
delivery systems for enhancing antibiotic therapy. Journal of Pharmaceutical Sciences. 
2015;104(3):872-905. 
2. Gupta A, Mumtaz S, Li C-H, Hussain I, Rotello VM. Combatting antibiotic-resistant 
bacteria using nanomaterials. Chemical Society Reviews. 2019;48(2):415-27. 
3. Grenni P, Ancona V, Caracciolo AB. Ecological effects of antibiotics on natural 
ecosystems: A review. Microchemical Journal. 2018;136:25-39. 
4. Santos R, Ruza D, Cunha E, Tavares L, Oliveira M. Diabetic foot infections: 
Application of a nisin-biogel to complement the activity of conventional antibiotics and 
antiseptics against Staphylococcus aureus biofilms. PloS one. 2019;14(7):e0220000. 
5. Hall CW, Mah T-F. Molecular mechanisms of biofilm-based antibiotic resistance and 
tolerance in pathogenic bacteria. FEMS Microbiology Reviews. 2017;41(3):276-301. 
6. Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of 
early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. 
Antimicrobial Agents and Chemotherapy. 2012;56(6):2795-805. 
7. Rehman K, Kamran SH, Akash MSH. Toxicity of antibiotics.  Antibiotics and 
antimicrobial resistance genes in the environment: Elsevier; 2020. p. 234-52. 
8. Boateng J. Drug delivery innovations to address global health challenges for pediatric 
and geriatric populations (through improvements in patient compliance). Journal of 
Pharmaceutical Sciences. 2017;106(11):3188-98. 
9. Denny KJ, De Wale J, Laupland KB, Harris PN, Lipman J. When not to start antibiotics: 
avoiding antibiotic overuse in the intensive care unit. Clinical Microbiology and Infection 
2020;26(1):35-40. 
10. Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A. Antimicrobial 
resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive 
Care Medicine. 2017;43(10):1464-75. 
11. Kavanagh KT. Control of MSSA and MRSA in the United States: protocols, policies, 
risk adjustment and excuses. Antimicrobial Resistance and Infection Control. 2019;8(1):1-8. 
12. Hos NJ, Jazmati N, Stefanik D, Hellmich M, AlSael H, Kern WV, et al. Determining 
vancomycin Etest MICs in patients with MRSA bloodstream infection does not support 
switching antimicrobials. Journal of Infection. 2017;74(3):248-59. 
13. Jiang X, Wang Y, Qin Y, He W, Benlahrech A, Zhang Q, et al. Micheliolide provides 
protection of mice against Staphylococcus aureus and MRSA infection by down-regulating 
inflammatory response. Scientific reports. 2017;7:41964. 
14. Tianshui L, Ying Q, Li D, Fayong L, Guoguang X. High-dose teicoplanin combined 
with daptomycin cured infective endocarditis and septic pulmonary embolism caused by 
methicillin-resistant Staphylococcus aureus: A case report and literature review. Burns Open. 
2019;3(3):126-8. 
15. Durand GA, Raoult D, Dubourg G. Antibiotic discovery: History, methods and 
perspectives. International Journal of Antimicrobial Agents. 2019;53(4):371-82. 
16. York A. New drugs for the antibacterial pipeline? Nature Reviews Microbiology. 
2020;18(2):61. 
17. Choi M, Hasan N, Cao J, Lee J, Hlaing SP, Yoo J-W. Chitosan-based nitric oxide-
releasing dressing for anti-biofilm and in vivo healing activities in MRSA biofilm-infected 




18. Hasan N, Cao J, Lee J, Hlaing SP, Oshi MA, Naeem M, et al. Bacteria-targeted 
clindamycin loaded polymeric nanoparticles: effect of surface charge on nanoparticle adhesion 
to MRSA, antibacterial activity, and wound healing. Pharmaceutics. 2019;11(5):236. 
19. Jamkhande PG, Ghule NW, Bamer AH, Kalaskar MG. Metal nanoparticles synthesis: 
An overview on methods of preparation, advantages and disadvantages, and applications. 
Journal of Drug Delivery Science and Technology. 2019;53:101174. 
20. Zhu YJ, Chen F. pH‐responsive drug‐delivery systems. Chemistry–An Asian Journal. 
2015;10(2):284-305. 
21. Rai VK, Mishra N, Yadav KS, Yadav NP. Nanoemulsion as pharmaceutical carrier for 
dermal and transdermal drug delivery: Formulation development, stability issues, basic 
considerations and applications. Journal of Controlled Release. 2018;270:203-25. 
22. Son G-H, Lee B-J, Cho C-W. Mechanisms of drug release from advanced drug 
formulations such as polymeric-based drug-delivery systems and lipid nanoparticles. Journal 
of Pharmaceutical Investigation. 2017;47(4):287-96. 
23. Sur S, Rathore A, Dave V, Reddy KR, Chouhan RS, Sadhu V. Recent developments in 
functionalized polymer nanoparticles for efficient drug delivery system. Nano-Structures and 
Nano-Objects. 2019;20:100397. 
24. Alshamsan A, Aleanizy FS, Badran M, Alqahtani FY, Alfassam H, Almalik A, et al. 
Exploring anti-MRSA activity of chitosan-coated liposomal dicloxacillin. Journal of 
microbiological methods. 2019;156:23-8. 
25. Norouz Dizaji A, Ding D, Kutsal T, Turk M, Kong D, Piskin E. In vivo 
imaging/detection of MRSA bacterial infections in mice using fluorescence labelled polymeric 
nanoparticles carrying vancomycin as the targeting agent. Journal of Biomaterials Science, 
Polymer Edition. 2020;31(3):293-309. 
26. Thakur K, Sharma G, Singh B, Chhibber S, Katare OP. Nano-engineered lipid-polymer 
hybrid nanoparticles of fusidic acid: an investigative study on dermatokinetics profile and 
MRSA-infected burn wound model. Drug Delivery and Translational Research. 
2019;9(4):748-63. 
27. Holmes AM, Heylings JR, Wan K-W, Moss GP. Antimicrobial efficacy and 
mechanism of action of poly (amidoamine)(PAMAM) dendrimers against opportunistic 
pathogens. International Journal of Antimicrobial Agents. 2019;53(4):500-7. 
28. Casadei MA, Cerreto F, Cesa S, Giannuzzo M, Feeney M, Marianecci C, et al. Solid 
lipid nanoparticles incorporated in dextran hydrogels: a new drug delivery system for oral 
formulations. International Journal of Pharmaceutics. 2006;325(1-2):140-6. 
29. Groo A-C, Matougui N, Umerska A, Saulnier P. Reverse micelle-lipid nanocapsules: a 
novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide. 
International Journal of Nanomedicine. 2018;13:7565. 
30. Bolhassani A, Javanzad S, Saleh T, Hashemi M, Aghasadeghi MR, Sadat SM. 
Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious 
diseases. Human Vaccines and Immunotherapeutics. 2014;10(2):321-32. 
31. Nagavarma B, Yadav HK, Ayaz A, Vasudha L, Shivakumar H. Different techniques 
for preparation of polymeric nanoparticles-a review. Asian Journal of Pharmaceutical and 
Clinical Research. 2012;5(3):16-23. 
32. Ahmad N, Ahmad R, Alam MA, Ahmad FJ, Amir M, Pottoo FH, et al. Daunorubicin 
oral bioavailability enhancement by surface coated natural biodegradable macromolecule 
chitosan based polymeric nanoparticles. International Journal of Biological Macromolecules. 
2019;128:825-38. 
33. Mehraban N, Musich PR, Freeman HS. Synthesis and encapsulation of a new zinc 
Phthalocyanine photosensitizer into polymeric nanoparticles to enhance cell uptake and 




34. Jurov A, Popović D, Rakić IŠ, Marion ID, Filipič G, Kovač J, et al. Atmospheric 
pressure plasma jet–assisted impregnation of gold nanoparticles into PVC polymer for various 
applications. The International Journal of Advanced Manufacturing Technology. 2019;101(1-
4):927-38. 
35. Jayawardhana AM, Qiu Z, Kempf S, Wang H, Miterko M, Bowers DJ, et al. Dual-
action organoplatinum polymeric nanoparticles overcoming drug resistance in ovarian cancer. 
Dalton Transactions. 2019;48(33):12451-8. 
36. Álvarez-Paino M, Muñoz-Bonilla A, Fernández-García M. Antimicrobial polymers in 
the nano-world. Nanomaterials. 2017;7(2):48. 
37. Ullah A, Qazi J, Rahman L, Kanaras AG, Khan WS, Hussain I, et al. Nanoparticles‐
assisted delivery of antiviral‐siRNA as inhalable treatment for human respiratory viruses: A 
candidate approach against SARS‐COV‐2. Nano Select. 2020. 
38. Choudhury H, Gorain B, Pandey M, Khurana RK, Kesharwani P. Strategizing 
biodegradable polymeric nanoparticles to cross the biological barriers for cancer targeting. 
International Journal of Pharmaceutics. 2019;565:509-22. 
39. Oshiro-Júnior JA, Rodero C, Hanck-Silva G, Sato MR, Alves RC, Eloy JO, et al. 
Stimuli-responsive Drug Delivery Nanocarriers in the Treatment of Breast Cancer. Current 
Medicinal Chemistry. 2020;27(15):2494-513. 
40. Canaparo R, Foglietta F, Giuntini F, Della Pepa C, Dosio F, Serpe L. Recent 
developments in antibacterial therapy: focus on stimuli-responsive drug-delivery systems and 
therapeutic nanoparticles. Molecules. 2019;24(10):1991. 
41. Thambi T, Lee DS. Stimuli-responsive polymersomes for cancer therapy.  Stimuli 
Responsive Polymeric Nanocarriers for Drug Delivery Applications: Elsevier; 2019. p. 413-
38. 
42. Sadhukhan P, Kundu M, Chatterjee S, Ghosh N, Manna P, Das J, et al. Targeted 
delivery of quercetin via pH-responsive zinc oxide nanoparticles for breast cancer therapy. 
Materials Science and Engineering: C. 2019;100:129-40. 
43. Liu J, Huang Y, Kumar A, Tan A, Jin S, Mozhi A, et al. pH-sensitive nano-systems for 
drug delivery in cancer therapy. Biotechnology Advances. 2014;32(4):693-710. 
44. Ding X, Wang A, Tong W, Xu FJ. Biodegradable Antibacterial Polymeric 
Nanosystems: A New Hope to Cope with Multidrug‐Resistant Bacteria. Small 
2019;15(20):1900999. 
45. Hassan D, Omolo CA, Fasiku VO, Mocktar C, Govender T. Novel chitosan-based pH-
responsive lipid-polymer hybrid nanovesicles (OLA-LPHVs) for delivery of vancomycin 
against methicillin-resistant Staphylococcus aureus infections. International Journal of 
Biological Macromolecules. 2020;147:385-98. 
46. Makhathini SS, Omolo CA, Gannimani R, Mocktar C, Govender T. pH-Responsive 
Micelles from an Oleic Acid Tail and Propionic Acid Heads Dendritic Amphiphile for the 
Delivery of Antibiotics. Journal of Pharmaceutical Sciences. 2020;109(8):2594-606. 
47. Kalhapure RS, Jadhav M, Rambharose S, Mocktar C, Singh S, Renukuntla J, et al. pH-
responsive chitosan nanoparticles from a novel twin-chain anionic amphiphile for controlled 
and targeted delivery of vancomycin. Colloids and Surfaces B: Biointerfaces. 2017;158:650-7. 
48. Kalhapure RS, Sikwal DR, Rambharose S, Mocktar C, Singh S, Bester L, et al. 
Enhancing targeted antibiotic therapy via pH responsive solid lipid nanoparticles from an acid 
cleavable lipid. Nanomedicine: Nanotechnology, Biology and Medicine. 2017;13(6):2067-77. 
49. Yan J, Wang Y, Zhang X, Liu S, Tian C, Wang H. Targeted nanomedicine for prostate 
cancer therapy: docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles 




50. Mandal B, Bhattacharjee H, Mittal N, Sah H, Balabathula P, Thoma LA, et al. Core–
shell-type lipid–polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine: 
Nanotechnology, Biology and Medicine. 2013;9(4):474-91. 
51. Zhang L, Zhu D, Dong X, Sun H, Song C, Wang C, et al. Folate-modified lipid–
polymer hybrid nanoparticles for targeted paclitaxel delivery. International Journal of 
Nanomedicine. 2015;10:2101. 
52. Bose RJ, Ravikumar R, Karuppagounder V, Bennet D, Rangasamy S, Thandavarayan 
RA. Lipid–polymer hybrid nanoparticle-mediated therapeutics delivery: advances and 
challenges. Drug Discovery Today. 2017;22(8):1258-65. 
53. Crucho CI. Stimuli‐responsive polymeric nanoparticles for nanomedicine. 
ChemMedChem. 2015;10(1):24-38. 
54. Joglekar M, Trewyn BG. Polymer‐based stimuli‐responsive nanosystems for 
biomedical applications. Biotechnology. 2013;8(8):931-45. 
55. Ling D, Li H, Xi W, Wang Z, Bednarkiewicz A, Dibaba ST, et al. Heterodimers made 
of metal–organic frameworks and upconversion nanoparticles for bioimaging and pH-
responsive dual-drug delivery. Journal of Materials Chemistry B. 2020;8(6):1316-25. 
56. Fraix A, Conte C, Gazzano E, Riganti C, Quaglia F, Sortino S. Overcoming 
Doxorubicin Resistance with Lipid–Polymer Hybrid Nanoparticles Photoreleasing Nitric 
Oxide. Molecular Pharmaceutics. 2020;17(6):2135-44. 
57. Radovic-Moreno AF, Lu TK, Puscasu VA, Yoon CJ, Langer R, Farokhzad OC. Surface 
charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of 
antibiotics. ACS nano. 2012;6(5):4279-87. 
58. Seedat N, Kalhapure RS, Mocktar C, Vepuri S, Jadhav M, Soliman M, et al. Co-
encapsulation of multi-lipids and polymers enhances the performance of vancomycin in lipid–
polymer hybrid nanoparticles: In vitro and in silico studies. Material Science and Engineering 
C. 2016;61:616-30. 
59. Jutooru I, Chadalapaka G, Chintharlapalli S, Papineni S, Safe S. Induction of apoptosis 
and nonsteroidal anti‐inflammatory drug‐activated gene 1 in pancreatic cancer cells by a 
glycyrrhetinic acid derivative. Molecular Carcinogenesis. 2009;48(8):692-702. 
60. Lefaki M, Papaevgeniou N, Tur JA, Vorgias CE, Sykiotis GP, Chondrogianni N. The 
dietary triterpenoid 18α–Glycyrrhetinic acid protects from MMC-induced genotoxicity 
through the ERK/Nrf2 pathway. Redox Biology. 2020;28:101317. 
61. Ming LJ, Yin ACY. Therapeutic effects of glycyrrhizic acid. Natural Product 
Communications. 2013;8(3):415-8. 
62. Kowalska A, Kalinowska‐Lis U. 18β‐Glycyrrhetinic acid: its core biological properties 
and dermatological applications. International Journal of Cosmetic Science. 2019;41(4):325-
31. 
63. Wang L, Yang R, Yuan B, Liu Y, Liu C. The antiviral and antimicrobial activities of 
licorice, a widely-used Chinese herb. Acta Pharmaceutica Sinica B. 2015;5(4):310-5. 
64. Wang L-J, Geng C-A, Ma Y-B, Huang X-Y, Luo J, Chen H, et al. Synthesis, biological 
evaluation and structure–activity relationships of glycyrrhetinic acid derivatives as novel anti-
hepatitis B virus agents. Bioorganic & Medicinal Chemistry Letters. 2012;22(10):3473-9. 
65. Oyama K, Kawada-Matsuo M, Oogai Y, Hayashi T, Nakamura N, Komatsuzawa H. 
Antibacterial effects of glycyrrhetinic acid and its derivatives on Staphylococcus aureus. PLoS 
One. 2016;11(11):e0165831. 
66. Madhumathi K, Rubaiya Y, Doble M, Venkateswari R, Kumar TS. Antibacterial, anti-
inflammatory, and bone-regenerative dual-drug-loaded calcium phosphate nanocarriers—in 




67. Wu J-L, Tian G-X, Yu W-J, Jia G-T, Sun T-Y, Gao Z-Q. pH-responsive hyaluronic 
acid-based mixed micelles for the hepatoma-targeting delivery of doxorubicin. International 
Journal of Molecular Sciences. 2016;17(4):364. 
68. Hefnawy A, Khalil IH, Arafa K, Emara M, El-Sherbiny IM. Dual-Ligand 
Functionalized Core-Shell Chitosan-Based Nanocarrier for Hepatocellular Carcinoma-
Targeted Drug Delivery. International Journal of Nanomedicine. 2020;15:821-37. 
69. Sun Y, Lu J, Yan D, Shen L, Hu H, Chen D. Cellular uptake mechanism and clearance 
kinetics of fluorescence-labeled glycyrrhetinic acid and glycyrrhetinic acid–modified liposome 
in hepatocellular carcinoma cells. Environmental Toxicology and Pharmacology. 2017;53:46-
56. 
70. Wang C-Y, Kao T-C, Lo W-H, Yen G-C. Glycyrrhizic acid and 18β-glycyrrhetinic acid 
modulate lipopolysaccharide-induced inflammatory response by suppression of NF-κB 































2.1 Introduction ........................................................................................................................ 16 
2.2 The burden of infectious diseases and limitations of antibiotic therapy ............................ 16 
2.3  Nanoengineered antibiotic delivery systems .................................................................... 19 
2.4 Lipid-polymer hybrid nanoparticles (LPHNPs) ................................................................. 21 
2.4.1 Main types of LPHNPs ................................................................................................... 22 
2.4.2 Main techniques of LPHNP preparation ......................................................................... 23 
2.4.3 LPHNPs characterization ................................................................................................ 25 
2.4.4 LPHNPs for antibiotic delivery ...................................................................................... 27 
2.4.5 Responsive LPHNPs for antibiotic delivery…………………………………………...27 
2.5 pH-Responsive LPHNPs .................................................................................................... 28 
2.6 Vancomycin as a model drug for antibiotic therapy .......................................................... 31 
2.6.1 VCM nano delivery systems ........................................................................................... 31 
2.7 Conclusion ......................................................................................................................... 32 


















Chapter Two – Literature review 
2.1 Introduction 
This chapter provides an overview of the burden of infectious diseases on the healthcare system 
and limitations of current antibiotic therapy that have led to the development of bacterial 
resistance. It also provides an overview of the characteristics of lipid-polymer hybrid 
nanoparticles, preparation and characterization techniques, outlines the use of pH-responsive 
NDDS as a strategy to influence the treatment of infectious diseases and concludes with an 
overview of VCM as a model drug. 
2.2 The burden of infectious diseases on the healthcare sector and the limitations of 
antibiotics 
Worldwide, infectious diseases pose a significant threat despite the advancement of scientific 
research (1). The burden of infectious diseases on the healthcare system is related to an increase 
in morbidity and mortality rates (Figure 1) with lower respiratory infections, lung cancer and 
tuberculosis (TB) being among the top ten foremost causes of death in developing and 
developed countries (2). Currently, lower respiratory tract infections are the leading cause of 
death in Africa since 2010, whereas, in South Africa, TB remains the leading cause of death 
(Figure 2) (3). 
 
 






Figure 2. Leading causes of death in South Africa (4). 
 
In 1928, the first antibiotic known as penicillin was discovered by bacteriologist, Alexander 
Fleming (5). In 1945, penicillin was used to treat bacterial infections (6) and thus marked the 
beginning of a new era of antibiotics. The discovery of conventional antibiotics contributed to 
the prevention and treatment of infectious diseases (7). Antibiotics are classified according to 
their mechanism of actions, such as cell wall synthesis inhibitors, protein synthesis inhibitors, 
cell membrane permeability inhibitors and nucleic acid synthesis inhibitors (Figure 3) (8). 
Antibiotics are produced in several dosage forms such as tablets, capsules (9), emulsions, gels 
(10), suppositories, creams and ointments (11). 
Despite the ability to prevent and treat infectious diseases, several limitations are associated 
with conventional antibiotics, such as inadequate drug concentration at infection sites, harmful 
side effects, decreased cellular absorption and solubility, non-sustained drug release, poor 
pharmacokinetic profiles and poor patient compliance (12-14). Such limitations, associated 
with the incorrect use and unlimited use of antibiotics, has led to the failure of infectious 





Figure 3. Commonly used antibiotics mechanism of actions (15). 
 
Figure 4. History of antimicrobial development and resistance of bacteria (16). 
Bacteria acquire antibiotic resistance intrinsically or by horizontal gene transfer (17). 
Multidrug-resistant and extreme drug-resistant (XDR) bacterial strains are resistant to multiple 
antibiotic classes. Such untreatable bacterial infections are associated with ineffective and 
highly toxic antibiotic therapy (18, 19).  Among universal bacterial pathogens, MRSA has 
developed resistance to methicillin and is responsible for skin and soft skin infections resulting 
in increased morbidity and mortality rates (19, 20).  
Despite the increase in antimicrobial resistance, the rate of development of new antimicrobials 
against MDR organisms is deteriorating (Figure 5) (20). The primary reasons include the 
massive cost involved in the production of new chemical entities, low return on investment and 
lengthy drug approval procedures. Thus, novel approaches have been investigated in order to 
enhance the delivery of conventional drug dosage forms  and to restore efficiency and 
effectiveness (21, 22), such as individualizing antibiotic treatment, therapeutic drug monitoring 





Figure 5. Declining number of new antibiotics (25). 
 
2.3 Nanoengineered drug delivery systems 
Nanotechnology is defined as the manipulation of atoms and molecules conducted on a 
nanoscale, used within scientific fields (26, 27). Nanotechnology within the field of medicine 
involves the synthesis and application of nanosized substances or compounds designed to 
maximize the outcome of therapy (28). Nanoparticles possess unique chemico-physical 
properties including, their subcellular size, large surface area to mass ratio, enhanced 
interactions between pathogen and host cells/tissues and ability to be modified structurally 
and functionally (29, 30).  
Nano drug delivery systems possess the ability to improve drug stability, increase drug 
absorption within target tissues and enhance localization, thus enhancing drug efficacy (31). 
Examples of NDDS, illustrated in Figure 6, encapsulating the various drug classes include 
liposomes (32), PNPs (33), dendrimers (34), micelles (35), lipid polymer hybrids (36), solid 
lipid nanoparticles (37) and nanostructured lipid carriers (38). Table 1 illustrates several types 
of nanocarriers entrapping antibiotics for the treatment of different bacterial infections.  
Nanosystems are applied in several routes for antibiotic administration such as oral, 
intravenous, inhalation, topical and transcutaneous (39).  
 
NDDS have several advantages over conventional antibiotics, which include targeted and 
sustained drug release at infection sites (40), selective targeting of tissues and cells (41, 42), 
improved cellular absorption and solubility (29, 42), improved drug stability, synergistic 
effects via co-delivery of antimicrobials (41, 43), enhanced patient compliance (42), minimized 
side effects (44) and potentiation of antibacterial activity (32). Due to the emergence of 
antibiotic resistant bacteria possessing evolved resistance mechanisms, innovative NDDS need 
to be developed to overcome antimicrobial resistance (45, 46). The various mechanisms by 
which nanosystems have the potential to overcome antimicrobial resistance include, increased 
concentration at the target site of infection, high entrapment efficiency of hydrophilic or 
lipophilic drugs, decreased dosage, protection of encapsulated drugs from bacterial enzymatic 
inactivation, increased uptake or decreased efflux, physical damage of the plasma membrane, 




overcome antibiotic limitations and offer a promising approach to combatting bacterial 
resistant pathogens (14).  
 
















Main findings Reference 
Polymeric 
nanoparticles 
Clindamycin MRSA - Enhanced antibacterial 
activity 
- Enhanced wound healing 
(51) 
Liposomes  VCM SA and MRSA - Sustained release 
- Enhanced in vitro 
antibacterial activity 
(32) 
Dendrimers  Ciprofloxacin SA and 
Escherichia coli 
- Co-administration of 
dendrimers reduced 
the required effective dose 
of the drug 
- Synergistic antibacterial 
activity 
(52) 
Micelles  VCM SA and MRSA - Sustained drug release  
- Enhanced in vitro and in 




Meropenem Escherichia coli - Sustained release  







- Sustained drug release 
- Enhanced drug 





Ciprofloxacin Escherichia coli - Enhanced antibacterial 
activity 
(54) 
Polymersomes VCM  SA and MRSA - Sustained drug release  
- Enhanced in vitro and in 
vivo antibacterial activity 
(55) 
 
2.4 Lipid-polymer hybrid nanoparticles 
Merging the structural components of liposomes and PNPs formulates LPHNPs (56). LPHNPs 
combine the potential advantages of liposomes and PNPs (56). Hybrid nanoparticles may be 
produced in different morphologies such as core shell and matrix LPHNPs (57). The core may 
be entrapped in single/multiple layers of the lipid on the polymer core material that may provide 
the site for surface functionalization with different targeting ligands and receptors to potentiate 
desired characteristics of LPHNPs (58). Natural or synthetic lipids such as, glycerol and its 
derivatives are amphiphilic molecules as well as convenient and inexpensive materials (59). 
Natural or synthetic polymers are stable, convenient and inexpensive materials for the 
production of numerous unique nanoparticle constructs with great potential applications in the 




63). Such polymers demonstrate enhanced efficacy, reduced toxicity, minimal environmental 
hazards and provide higher resistance against MDR bacteria. Hence, the development of 
dynamic and non-toxic antimicrobial lipid-polymer hybrid nanoparticles are recommended for 
the treatment infectious diseases (64, 65). Well known synthetic polymers include polylactides 
(PLA), polyglycolides (PGA), an example of a copolymer is polylactide co-glycolides (PLGA) 
(58) and natural polymers include chitosan (66-68), alginate, albumin and gelatin (69). Figure 




Figure 7. Lipid-polymer hybrid nanoparticle structure (70). 
2.4.1 Main types of lipid-polymer hybrid nanoparticles 
2.4.1.1 Monolithic lipid-polymer hybrid nanoparticles 
Monolithic or mixed lipid polymer hybrids are made up of a polymeric matrix in which the 
lipid molecules are dispersed throughout (69). The monolithic LPHNPs are structurally 
comprised of copolymers and lipids as shown in Figure 8 (69). The applications include 
localized drug delivery, tissue engineering and cancer immunotherapy (70). 
2.4.1.2 Biomimetic lipid-polymer nanoparticles 
These nanoparticles are coated with red blood cell and also known as erythrocyte membrane-
camouflaged PNPs (71). Lipid bilayer-coated nanoparticles are prepared by extrusion of 




nanoparticles are widely applied in the fields of bioimaging, gene therapy and tissue 
engineering (72).  
2.4.1.3 Polymer-caged liposomal nanoparticles 
These are stable systems formed when polymers are anchored on the surface of liposomes (73). 
Their applications in the medical field include bioimaging and tissue engineering (74).  
2.4.1.4 Core shell lipid-polymer hybrid nanoparticles 
There are two types of core shell LPHNPs namely, polymer core-lipid shell nanoparticles (75) 
and hollow core-lipid-polymer-lipid nanoparticles (76). Such systems have a multi layered 
structure comprising of a polymeric nucleus, lipid-PEG and lipids in the outermost layers 
acting as the shell (77). Their applications include immunology kits and biosensors for 
magnifying biomolecular identification (78). Figure 8 depicts the structural image of the four 
main types of lipid-polymer hybrid nanoparticles. 
 
 
Figure 8. Four main types of LPHNPs (79). 
 
2.4.2 Main techniques of lipid-polymer hybrid nanoparticle preparation 
Several methods have been applied to produce LPHNPs from lipids and preformed polymers, 
including solvent evaporation (80), nanoprecipitation (81), emulsification (82), dialysis and 




polymerization of monomers, such as emulsion, micro-emulsion, mini-emulsion and interfacial 
polymerization (58, 83).  
Solvent evaporation was the first method developed to prepare LPHNPs (84). Using the 
method, shown in Figure 9, emulsions can be formulated by firstly, dissolving in volatile 
organic solvents. Then the emulsion is transformed into a nanoparticle suspension via 
evaporation of the solvent from the polymer. Two processes have been applied for the 
formulation of emulsions: 1) oil-in-water (single emulsions) and 2) (water-in-oil)-in-water 
(double emulsions). High-speed homogenization or ultra-sonication takes place followed by 
solvent evaporation and thereafter magnetic stirring at room temperature. LPHNPs are 
centrifuged and washed to remove unwanted substances (84-86).  
 
Figure 9. Solvent evaporation technique (58). 
 
Micro-emulsion polymerization is a novel and effective approach for nanoparticle preparation 
(87). Particle size and the number of chains per particle are considerably lower in micro-
emulsion polymerization as compared to emulsion polymerization (58, 88, 89). A water-
miscible initiator is immersed into the aqueous phase of a thermodynamic micro-emulsion.  
Thereafter, the surfactant and all initiator molecules within the system are used up by the 
polymer particles. The reaction mixture consisting of swollen polymer micelles with dissolved 








Figure 10. Micro-emulsion technique (92). 
 
2.4.3 Lipid-polymer hybrid nanoparticle characterization 
Several methods are applied for the characterization of LPHNPs in order to explore their 
potential application, stability and kinetic profiles. LPHNPs are characterized in terms of 
particle size, PDI, surface charge/ZP, morphology and other parameters depending on LPHNPs 
applications (93, 94). 
 
2.4.3.1 Particle size and size distribution  
Dynamic light scattering (DLS) is a technique used to determine size distribution of submicron 
particles or polymers in a formulation. The DLS technique is most frequently used for 
determining particle size and PDI as it is quick, practical and manageable (95-98). The 
instrument used to measure particle size and PDI is a Zetasizer. The rate at which the intensity 
of the scattered light fluctuates depends on the size of the particles (95). 
 
2.4.3.2 Surface charge 
The ZP of nanoparticles is a crucial indicator of the stability of LPHNPs during storage. A high 
positive or negative surface charge indicates high electrostatic repulsion, thus, avoiding the 
formation of LPHNP agglomerates; hence improved stability of the nanosystem is maintained. 
Analytical instruments based on the DLS technique is used for ZP measurement (99-102). 
 
2.4.3.3 Morphology  
Scanning electron microscopy (SEM) produces images of a sample by scanning the surface of 




Electrons interact with the sample providing data about surface morphology and sample 
composition. SEM technique is advantageous for nanoparticle size and shape characterization 
due to easy preparation and fast image acquisition (99, 102). Similarly, transmission electron 
microscopy (TEM) produces images of a sample whereby an accelerated beam of electrons 
penetrates through a sample. The instrument used is a transmission electron microscope. 
Electrons interact with the sample providing data on structure and morphology. TEM is a 
standard method for measuring nanoparticle size, size distribution and morphology (101). 
Amorphous particles usually demonstrate a spherical shape, small nanoparticles form clusters 
and various shapes like rods and fibers can also be identified on the range of 1-1000 nm (100, 
103).  
 
2.4.3.4 Entrapment efficiency 
Drug entrapment efficiency (EE) is the concentration of drug entrapped within the matrix of 
LPHNPs. The unentrapped or free drug is separated from the LPHNPs via ultra-centrifugation 
and ultra-filtration methods, followed by quantification of the free drug using UV or HPLC 
analysis (104-106).  
 
2.4.3.5 Thermal profiles 
Analytical instruments based on differential scanning calorimetry (DSC) techniques are used 
to analyze the crystallization form and thermal profile of LPHNPs (107). This technique uses 
a differential scanning calorimeter instrument. DSC analysis can measure melting temperature, 
glass transition temperature, reaction energy, crystallinity, precipitation energy and 
temperature (105). 
 
2.4.3.6 In vitro drug release 
Drug release studies are commonly carried out using a dynamic dialysis bag method to 
investigate the release behaviour of drug loaded LPHNPs, followed by quantification of the 
drug concentration using a reliable analytical method, such as UV or HPLC (108). Factors such 
as particle size (surface area) of LPHNPs can influence drug release behaviour. Smaller 
particles have a larger surface area to volume ratio, hence the drug associated with small 
nanoparticles would be situated at/near the surface resulting in a faster drug release (107, 108). 
Several other characterization analyses can be done, such as antibacterial studies (98) and 
haemolysis assays (109) for antibacterial research, cytotoxicity studies (84) for anticancer 




engineering studies (110). Hence the type of characterization assessment depends on the 
application of the LPHNPs.  
 
2.4.4 Lipid-polymer hybrid nanoparticles for antibiotic delivery 
Antibiotic-loaded LPHNPs have emerged as one of the promising formulations in antibiotic 
therapy against infections (111). Advantages associated with LPHNPs used for antibiotic 
delivery are their stability during storage, easy preparation techniques and functionalization, 
controlled antibiotic release, improved biocompatibility and enhanced circulation time (112). 
The subcellular size of LPHNPs allows them to effectively penetrate the target site and release 
the antibiotic locally, enhancing localization and antibiotic concentration at the infection site 
(113). Different antibiotics can be incorporated into LPHNPs for different routes of 
administration such as, oral, topical, transdermal, ocular and intravenous (114, 115).  
2.4.5 Responsive lipid-polymer hybrid nanoparticles for antibiotic delivery 
First generation nanoparticles were developed and approved more than 15 years ago. Second 
generation nanocarriers advanced this field by achieving long blood circulation and passive 
targeting (116, 117). While third generation nanocarriers aimed at achieving molecular 
recognition and active targeting, hence the development of stimuli-responsive nanoparticles 
(116, 117). Recent scientific advancements focus on developing stimuli-responsive 
nanosystems that release the drugs only when triggered by pH, enzymes, temperature, electric 
field and magnetic field (118-122). The stimuli-responsive drug delivery strategy can provide 
targeted drug release, improved tissue and cellular internalization and drug accumulation at 
targeted sites (123). This can result in enhanced drug stability, bioavailability and therapeutic 
efficacy (124).  
Despite the advancements of LPHNPs application incorporating different drug classes via 
different routes of administration such as oral (125-127), topical (128, 129), intravenous (130, 
131), few studies have been reported for drug delivery via responsive LPHNPs, but with great 
potential. Li et al. reported enzyme-responsive lipid-polymer hybrid vesicles for bacterial-
strain-selective delivery system for antibiotics (128), Moreno et al. reported pH-responsive 
LPHNPs for bacterial cell wall targeted delivery of antibiotics (129) and Michalak et al. 
reported antibiotic-loaded temperature-responsive LPHNPs against SA (130). Advantages of 
responsive LPHNPs include enhanced systemic release, enhanced internalization, improved 




2.5 pH-Responsive LPHNPs 
Current investigations of pH-responsive drug delivery systems have received much attention 
(132). As certain organs, cellular and tissue compartments exhibit different pH values, such as 
the blood, lysosomes, endosomes and gastrointestinal tract (mouth, stomach, duodenum, colon) 
(132). Diseases such as cancer (120), TB (133), H1N1 influenza virus (134), 
Alzheimer's disease (135), chronic lung diseases (136) and infections (bacterial, viral, fungal 
and parasitic) present with an acidic pH change different from the physiological pH of 7.4.  
The human body maintains a slightly alkaline pH of 7.2, but certain conditions such as 
hypoxemia, whereby there is low oxygen in the blood leading to an oxygen deficiency in the 
tissues, otherwise known as hypoxia, can ultimately result in bodily acidosis and inflammation. 
Decreased oxygen intake/decreased pH (acidic pH) allows bacteria, viruses and cancer cells to 
thrive (137, 138). During an infection, serum lactate dehydrogenase enzyme level increases, 
anaerobic conditions develop and lactate production increases from pyruvate (139). Increased 
lactate levels elevate the production and accumulation of proinflammatory cytokines and 
oxygen reactive species (ROS) resulting in oxidative stress (139, 140). Lactate production 
continues to increment as the acidic environment increases (139, 140). This indicator can 
potentially trigger the design of pH-responsive nanosystems for targeted drug release (140-
142). Hence, stimuli-responsive nanosystems, specifically pH-responsive drug delivery 
systems, can be more promising drug delivery systems than conventional NDDS. Table 2 
summarizes the studies reported on pH-responsive drug delivery of LPHNPs.  
At acidic conditions, pH-responsive nanoformulations operate via two mechanisms of action: 
1) Protonation: pH-Responsive materials possess ionizable groups that remain 
unprotonated, while in acidic pH, these groups undergo protonation and a reversal of 
surface charge, leading to conformational variations followed by drug release.  
2) Hydrolysis of labile acid bonds: pH-responsive materials can form an acid-labile bond 
with a drug that undergoes hydrolysis at acidic conditions, resulting in a targeted 
antibiotic release (121, 141, 143). 
 
Some bacterial infections, such as SA and E. coli, are acidic and produce acetic acid and lactic 
acid under oxygen deprived conditions. Therefore, the pH-responsive approach is 
advantageous in reduced exposure of the antibiotic to non-infected sites, improving targeted 




which can enhance the antibacterial activity, ultimately preventing the development of bacterial 
resistance (129). Thus, pH-sensitive nanocarriers can impact infectious disease therapy by 
improving antibiotic protection at the acidic infection site, improving biofilm penetration, 
enhancing antibacterial activity and enhancing targeted release, thus enhancing the 



























Table 2.  Examples of pH-responsive lipid-polymer hybrid nanoparticle delivery systems that 
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2.6. Vancomycin as a model drug for antibiotic delivery 
Vancomycin is a tricyclic glycopeptide antibiotic (Figure 14), which is the ‘last resort’ drug 
against MRSA infections. Vancomycin functions by forming a complex with the D-Ala-D-
Ala terminals, thereby inhibiting the function of peptidoglycan synthetase enzyme and 
subsequently preventing elongation of peptidoglycan matrix and  cell wall synthesis (151-
153). Intravenous administration of VCM is associated with severe side effects, such as 
thrombophlebitis (154), neutropenia, nephrotoxicity (155), ototoxicity, thrombocytopenia and 
most commonly red man or red neck syndrome (156).  
 
2.6.1 Vancomycin nano delivery systems 
Vancomycin is a large hydrophilic molecule, which accounts for its low bioavailability, cellular 
absorption and penetration (157). The bactericidal activity of VCM is aimed at attaching to the 
bacterial cell wall rather than to a protein target, initially VCM was immune to resistance (158). 
However, the emergence of two complex resistance mechanisms involving a multi-enzyme 
pathway compromised the efficacy of the drug (159). Resistance to the drug involves 
breakdown of D-Ala-D-Ala terminals and its replacement with D-Ala-D-lac or D-Ala-D-Ser 
regions to which VCM has low affinity (158, 160). Vancomycin resistance is a progressing 
healthcare issue that has led to the failure of VCM treatment and increased minimum inhibitory 
concentration (MIC) (161). Vancomycin NDDS has shown to be highly effective as compared 
to VCM conventional dosage forms. The liposomal-VCM formulation had enhanced 
antibacterial performance and sustained circulation time (162, 163), while VCM-PNPs had 
enhanced antibacterial activity and biocompatibility with tissues (14). VCM-LPHNs showed 
sustained drug release and antimicrobial activity (36). Omolo et al. reported VCM-loaded 
polymersomes that enhanced its anti-MRSA activity (55). 
On the other hand, pH-responsive VCM-PNPs have been reported for enhancing VCM targeted 
delivery (129, 164). Kalhapure et al. (2017) (164) reported PNPs with size of 220.57 ± 5.9 nm 
and ZP of 21.9 ± 0.9 mV showed higher antibacterial activity, compared to Moreno et al. (2012) 
(129) who reported PNPs with size of 196.0 ± 7.8 nm and ZP of 2.3 ± 1.0 mV. Hence, a more 
positive ZP could lead to improved antibacterial activity. Kalhapure et al. (2017) also reported 
acid cleavable lipids for pH-responsive VCM-SLNs formulation; their results showed 
enhanced antimicrobial activity against MRSA and SA (165). Makhathini et al. (2020) (166) 
and Sonawane et al. (2020) (14) reported pH-responsive VCM-micelles with results showing 




compared to physiological pH of 7.4. Sonawane et al. (2020) (14) reported micelles with size 
of 130.33 ± 7.36 nm and ZP of -4.33 ± 0.55 mV, which showed superior antibacterial activity 
than the VCM-micelles reported by Makhathini et al. (2020) (166) with size of 84.16 ± 0.184 
nm and ZP of -42.6 ± 1.98 mV. Hence smaller particle size and a less negative ZP could lead 
to better antibacterial activity. 
Wu et al. (2020) reported pH-responsive VCM-carbon dots against staphylococcal biofilms, 
which showed enhanced VCM penetration and killing of non-extracellular-polymeric-
substance producing staphylococcal strains (167). Osman et al. (2019) reported pH-responsive 
VCM-nanostructured lipid carriers against SA and MRSA; their results indicated enhanced 
antibacterial activity (38). Zhang et al. (2020) (168) reported VCM-hybrid magnetic 
nanoparticles formulation; which resulted in enhanced antimicrobial activity against SA and E. 
coli. Xie et al. (2020) (169) reported pH-responsive VCM-silver nanoparticles formulation; 
their results showed enhanced antibacterial activity against MRSA and E. coli. Salih et al. 
(2020) (170) reported pH-responsive VCM-nanovesicles formulation; which demonstrated 
enhanced antibacterial activity against SA and MRSA . Thus, pH-responsive nanosystems for 
VCM targeted delivery can enhance VCM activity, overcome the limitations of VCM 
conventional dosage forms and combat bacterial resistance. 
 
2.7 Conclusion  
This chapter highlighted the potential of nano delivery systems to improve the treatment of 
bacterial infections and combat antimicrobial resistance. Nanocarriers that are pH responsive 
are emerging as a siginificant strategy to potentiate the performance of nanocarriers for 
overcoming the restrictions of antibiotic therapy and curbing the evolution of a post-antibiotic 
era. Furthermore, the chapter also demonstrated that vancomycin is an ideal model drug being 
widely used to develop novel nanosystems to treat bacterial infections. Novel pH-responsive 
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Abstract: Despite advancement in the control and therapeutics of infectious diseases, 
antimicrobial resistance remains a global burden. Hence there is a need for novel strategies that 
improve and potentiate available antibiotics to prevent a regress to a pre-antibiotic era. This 
study aimed to co-deliver vancomycin (VCM) and 18β-glycyrrhetinic acid (GA) via pH-
responsive lipid-polymer hybrid nanoparticles (VCM-GAPAH-LPHNPs) to explore its 
potential for enhanced activity and targeted delivery of VCM. The stability of VCM-GAPAH-
LPHNPs were supported by in silico studies. Biosafe VCM-GAPAH-LPHNPs were prepared 
using the microemulsion technique. VCM-GAPAH-LPHNPs demonstrated size, 
polydispersity index, zeta potential and encapsulation efficiency of 198.4 ± 0.302 nm, 0.255 ± 
0.003, -3.8 ± 0.335 mV and 69.46 ± 2.52 %, respectively. In vitro drug release studies revealed 
that VCM-GAPAH-LPHNPs had sustained and faster release at acidic conditions compared to 
bare VCM. VCM-GAPAH-LPHNPs also demonstrated greater in vitro antibacterial potential 
against methicillin-resistant Staphylococcus aureus by 16-fold, when compared to the bare 
drug. Additionally, the time-killing assay indicated the ability of VCM-GAPAH-LPHNPs to 
eliminate 75 % of MRSA in less than 12 h. Furthermore, crystal violet assay confirmed VCM-
GAPAH-LPHNPs potential to eliminate biofilms. Therefore, these novel LPHNPs may serve 
as promising nanocarriers for enhancing antibiotic drug delivery and antibacterial activity. 
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Globally, infectious diseases primarily due to bacterial infections, are considered one of the 
main contributors towards increasing morbidity and mortality rates (1, 2). The WHO reported 
that more than 17 million deaths are caused by infectious diseases per year (3). Recent data 
indicate that by 2050, more individuals will die from bacterial diseases than any other disease, 
including cancer (4). Moreover, by then, approximately 4 million deaths are predicted in Africa 
due to antimicrobial resistance, with a possibility of higher death rates if appropriate measures 
are not undertaken (5). Hence, urgent interventions are required for the development of novel 
and innovative strategies to curtail current and emerging antibiotic-resistant pathogenic 
bacterial strains that are no longer sensitive to conventional antibiotics (6, 7).  
Current traditional antibiotic dosage forms possess various limitations, including suboptimal 
drug concentration at infection sites, high exposure to healthy cells, frequent administration of 
high doses and prolonged therapy (8-10). This results in sub-optimal drug delivery and activity, 
increased adverse effects, the toxicity of cells/tissues and poor patient compliance, thus 
contributing to poor outcomes and development of antibiotic resistance (11, 12). Hence, the 
engineering, formulation and application of novel drug delivery systems (NDDS) are explored 
(9) as an advanced strategy to suppress the limitations related to conventional dosage forms 
that contribute to antimicrobial resistance (13, 14).  
Novel drug delivery systems have showcased their potential in addressing the disadvantages 
related to conventional antibiotics by enhancing drug delivery at target sites of infection due to 
their subcellular size, biocompatibility with host cells/tissues and sizeable surface area to mass 
ratio (9, 15, 16). Lipid-polymer hybrid nanoparticles (LPHNPs) are one of the promising 
systems that are currently being employed to deliver drugs efficiently (17, 18). LPHNPs 
combine the mechanical advantages of polymeric nanoparticles and prowess of lipidic systems 
(17, 19). They are core-shell self-assembled nanosystems composed of a hydrophobic lipid 
core and a polymeric shell (20). Flexibility in the formulation of LPHNPs allows the 
formulation of the system that has programmable ability to respond to stimuli (21, 22). This 
can be achieved by focusing on the biofunctional property of the nanoparticle matrix in order 
to introduce targeted drug delivery and enhanced activity (23). The advancement in the field 
of nanotherapeutics has encouraged the development of pH-responsive nanosystems for 
effective and efficient antibiotic delivery (24-26). However, there are few reports on employing 




designed to have programmable destabilization and release the drug due to changes in pH that 
are synonymous with bacterial infection sites (27, 28). 
Plants contain rich sources of bioactive phytochemical compounds that are active against a 
wide spectrum of activity, 18β-glycyrrhetinic acid (GA) is such a compound (29, 30). It is a 
pentacyclic triterpenoid metabolite of a hydrolyzed product of glycyrrhizic acid from the 
Glycyrrhiza glabra (liquorice) plant (31). This bioactive compound has been reported to have 
anti-allergic (32), antibacterial, antiviral, antitumor and anti-inflammatory properties (33, 34). 
Due to the antibacterial activity of GA, it can be explored by co-delivery with other antibiotics 
in the market for synergistic action and augmentation of antibacterial drugs in the market (33, 
35). 
Surveys from the literature show combinational therapy of antibiotics in the market and 
bioactive compounds from natural sources have shown to enhance antibacterial activity (36). 
However, currently, there are no reports of GA being co-delivered with antimicrobial agents in 
the market in a nanosystem to target bacterial infectious diseases. Therefore, the combination 
of GA and antibiotics can further be explored by co-loading in a stimuli-responsive nanosystem 
for targeted and further enhancement of antimicrobial activity (37). Such a system will also 
contribute to the advancement of the pharmaceutical field. 
There are several reports of co-delivering GA with cancer and inflammatory drugs loaded in 
nanosystems for the treatment of cancer diseases (37-40). However, from our search of the 
literature, such a formulation for co-delivery of GA and antibiotics has not been reported 
before. We herein report vancomycin (VCM) and GA loaded LPHNPs that was coined from 
PAH and OA. This is the first report of LPHNPs for co-delivery of a hydrophilic drug and 
hydrophobic antibacterial agent in a pH-responsive drug delivery system for targeting bacteria. 
Therefore, the aim of this study was to formulate a multifunctional LPHNP that is pH-
responsive and co-loaded with two antibacterial agents. We envisage enhanced antibacterial 
activity due to the synergistic activity of the two loaded antibacterial agents, in addition to pH-
responsive targeted delivery of VCM and GA as a result of protonation and deprotonation of 
the OA and PAH. In basic media, OA will deprotonate becoming negatively charged and it 
will electrostatically combine with the positive amines of PAH, while in acidic media both OA 
and PAH protonate and both molecules become positively charged thus repelling each other. 
Hence, the disintegration of the LPHNPs system will lead to an increase in drug release. 




in basic media to positive in acidic media. To the best of our knowledge, such a multifunctional 
LPHNP system has never been reported before. 
Furthermore, no study has reported the pH-responsive co-delivery of VCM and GA 
nanoparticles to target bacteria. The advantages of the co-delivery of both hydrophilic and 
hydrophobic agents for combinational therapy, pH-responsive release for targeted delivery of 
VCM and GA and surface charge switching of the systems to target the negatively charged 
bacterial cell membrane can potentiate antibacterial effects of the system by acting in different 
mechanisms. The formulation and evaluation of this novel multifunctional LPHNP are reported 
in this paper.  
2. Materials and Methods    
2.1 Materials 
18β- Glycyrrhetinic acid, polyallylamine hydrochloride (PAH), Tween 80, VCM 
hydrochloride, oleic acid (OA), dialysis tubing cellulose membrane, Mueller Hinton broth 2 
(MHB) were obtained from Sigma-Aldrich (USA). Mueller Hinton Agar (MHA) and Nutrient 
Broth were obtained from Biolab Inc. (South Africa). Milli-Q purified water was obtained from 
an Elix® water purification system Millipore Corp. (USA). Sheep blood was purchased from 
United Scientific SA cc. (South Africa). Bacterial strains used were Staphylococcus aureus 
(Rosenbach) (ATCC®BAA-1683) (MRSA) and Staphylococcus aureus (ATCC 25922) (SA). 
The CACO-2 and HepG2 cell lines were purchased from ATCC.  
2.2 Molecular dynamics of components of oil phase, water phase and both phases 
To study the stability of the oil phase and water phase independently and then the assembly of 
the oil and water phase to form a complex, the AMBER suite was used to simulate the oil phase 
components, GA and OA, then separately the water phase components including PAH, VCM 
and Tween 80 and finally both oil and water phase components. Molecular dynamic 
simulations represent an all-encompassing toolkit that delves into the atomic arrangement 
within molecules, thus providing novel perspectives on the structural movements of molecular 
systems. The molecular dynamics simulations were carried out using the PMEMD engine of 
the AMBER software package with GPU acceleration (41). Gasteiger charges were used to 
charge compounds and ANTECHAMBER was used to create atomic partial charges using the 
General AMBER Force Field and Restrained Electrostatic Potential (RESP) methods. The 




the addition of hydrogen atoms and chloride and sodium ions and suspended the systems in an 
orthorhombic box of TIP3P water molecules such that all atoms were within 10 Å of the box 
edges. The protein residues were renumbered due to missing residues in the initial crystal 
structure. An initial minimization was performed for 2500 steps with a restraint potential of 10 
kcal.mol-1Å-2 to the solutes and for 500 steps of steepest descent followed by 500 steps of the 
conjugate gradient. This was followed by 1000 steps of full minimization Langevin thermostat, 
with a collision frequency of 1.0 ps-1 with harmonic restraint of 5 kcal.mol-1 Å-2 on the solutes, 
applied during the gradual heating up of the systems to a temperature of 300 K in the canonical 
ensemble for 50 ps. This was followed by 50 ps of density equilibration in isothermal–isobaric 
ensemble and a final 500 ps equilibration at 300 K, 1 bar pressure and a coupling constant of 2 
ps. The simulations were performed for 500 ns using classical molecular dynamics with a time 
step of 2 fs, with the frame being recorded at every 500 steps of simulation. All the bond lengths 
involving hydrogen atoms were constrained using the SHAKE algorithm (42). All the MD 
simulations were carried out using the GPU Amber 14 software package (43).  
2.3 Preparation of VCM-GAPAH-LPHNPs 
A previously reported micro-emulsion technique was used to prepare the VCM and GA loaded 
pH-responsive LPHNPs (44). Briefly, the oil phase, consisting of OA (40 mg) and GA (10 mg) 
was dissolved in ethanol (2 ml). While the aqueous phase was prepared by dissolving PAH (10 
mg), VCM (10 mg) and Tween 80 (20 mg) in 20 ml distilled water. The oil phase was added 
in a dropwise manner to the aqueous phase under stirring overnight at 500 rpm. 
2.4 Size, Polydispersity Index (PDI), Zeta Potential (ZP) and Morphology  
The size, PDI and ZP of VCM-GAPAH-LPHNPs were determined by the dynamic light 
scattering (DLS) technique using a Zetasizer Nano ZS90 instrument (Malvern Instruments 
Ltd., UK) at 25 °C. An aliquot of LPHNPs was appropriately diluted with phosphate buffers 
(pH 7.4, 6 and 4.5) to obtain concentrations that were within the system’s sensitivity range, the 
experiments were performed in triplicate (44, 45). 
The morphology of VCM-GAPAH-LPHNPs was determined by transmission electron 
microscopy (TEM). Samples were suitably diluted, stained with 1 % uranyl acetate (UA) 
solution, air-dried and visualized using a TEM (JOEL JEM-1010, Japan) operating at an 




2.5 Entrapment efficiency (EE%) and drug loading (DL%) 
The EE% and DL% of VCM-GAPAH-LPHNPs were determined by an ultrafiltration method. 
Briefly, LPHNPs emulsion (3 ml) was inserted into Amicon® Ultra-4 centrifugal filter tubes 
(Millipore Corp., USA) with 10 kDa pore size and centrifuged at 2000 rpm at 25 °C for 20 min 
(14). The unentrapped VCM was detected using a validated High-Pressure Liquid 
Chromatograph (Shimadzu, Japan) with UV detection at λ 280 nm. The mobile phase, 
consisting of water with 0.1 % trifluoroacetic acid (TFA) and acetonitrile (85/15 v/v), was 
pumped through a Nucleosil 100-5C18 column (150 mm X 4.6 mm in diameter) at a flow rate 
of 1 ml per min and an injection volume of 100 μl, with a regression equation of Y = 0.0044 x 
– 0.0013 and linearity coefficient (R2) of 0.9997. EE% and DL% were calculated using 
equations (1) and (2) below (27, 47). 
𝐄𝐄 (%) = (
𝐖𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐕𝐂𝐌/𝐆𝐀 𝐢𝐧 𝐋𝐏𝐇𝐍𝐏𝐬
𝐖𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐕𝐂𝐌/𝐆𝐀 𝐚𝐝𝐝𝐞𝐝
) ×  𝟏𝟎𝟎  (1) 
𝐃𝐋 (%)  = (
𝐖𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐕𝐂𝐌/𝐆𝐀 𝐢𝐧 𝐋𝐏𝐇𝐍𝐏𝐬
𝐓𝐨𝐭𝐚𝐥 𝐰𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐧𝐚𝐧𝐨𝐩𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬
) ×  𝟏𝟎𝟎  (2) 
2.6 Thermal profiles  
Differential scanning calorimetry (DSC) using a DSC-60 (Shimadzu, Japan) was used to 
determine the thermal profiles of the bare VCM, GA, physical composition and lyophilized 
drug-loaded LPHNPs. Briefly, each sample (2 mg) was placed in an aluminium pan and sealed. 
The scanning was done at a temperature range of 30 °C - 300 °C at a constant rate of 10 °C/min 
under a constant nitrogen flow of 10 ml/min, an empty pan was used as a reference (48). 
2.7 In vitro drug release and release kinetics 
The in vitro release studies were performed using a dialysis bag technique to investigate the 
release profile and mechanism of VCM-loaded GAPAH-LPHNPs. Dialysis bags with a pore 
size of 8000–14,400 Da containing the VCM-GAPAH-LPHNPs (VCM/GA 0.5 mg/ml each) 
were placed in PBS (40 ml) of pH 6 and 7.4 at 37 °C in a shaking incubator at 100 rpm. At 0.5, 
1, 2, 3, 4, 5, 6, 7, 8, 24, 48, 72 h, the samples (3 ml) were withdrawn and replaced with equal 
quantities of the fresh PBS solutions of pH 6 and 7.4 to maintain a constant volume. The 
amount of VCM released per time interval was determined by HPLC (Shimadzu, Japan) with 
UV detection set at λ 280 nm, with a regression equation of Y = 14129 x + 115582 and linearity 




Drug release kinetics were analysed using the DDSolver software program [60]. Six 
mathematical models, namely zero order, first order, Higuchi, Hixson-Crowel, Korsmeyer-
Peppas and Weibull were used to calculate and compare the correlation coefficient (R2) and 
root-mean-square error (RMSE) values. 
2.8 In vitro cytotoxicity 
The biocompatibility of VCM-GAPAH-LPHNPs was determined using the MTT assay 
following a previously reported method (50) on two cell lines, which included human intestinal 
epithelial cancer cells and human liver adenocarcinoma cells (CACO-2 and HepG2, 
respectively). Briefly, the cell lines were cultured and supplemented with 10 % foetal bovine 
serum (FBS), 1 % streptomycin and penicillin solution and 1 % L-glutamine, which were 
incubated at 37 ℃ in a humidified atmosphere of 5% carbon dioxide (CO2). Following 80 % 
confluency, the cell lines were seeded into a 96-well plate. After incubation for 24 h, the culture 
medium containing the treatment samples (20, 40, 60 and 80 μg/ml) were replaced with fresh 
culture medium (100 μl per well) and MTT solution (20 μl per well). After 4 h of incubation, 
the culture media and MTT assay solutions were immediately removed and dimethyl sulfoxide 
(100 μl) was added to each well to solubilize the MTT formazan crystals. The absorbance 
corresponding to each well was measured at λ 570 nm (Spectrostar Nano, Germany); all 
experiments were performed in triplicate. Equation (3) was used to determine the percentage 
cell viability: 
𝐂𝐞𝐥𝐥 𝐯𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲 (%) = (
𝐀𝟓𝟕𝟎𝐧𝐦 𝐭𝐫𝐞𝐚𝐭𝐞𝐝 𝐜𝐞𝐥𝐥𝐬
𝐀𝟓𝟕𝟎𝐧𝐦 𝐮𝐧𝐭𝐫𝐞𝐚𝐭𝐞𝐝 𝐜𝐞𝐥𝐥𝐬 
) ×  𝟏𝟎𝟎   (3) 
2.9 Haemolysis 
Haemolytic toxicity of VCM-GAPAH-LPHNPs was determined at different concentrations 
(15). Briefly, sheep blood was washed thrice with an isotonic 0.1 M PBS solution (pH 7.4) by 
centrifugation at 3000 rpm for 5 min. For each sample, VCM-GAPAH-LPHNPs formulation 
was diluted with 0.1 M PBS to obtain concentrations ranging from 0.05 to 0.5 mg/ml. The red 
blood cell (RBC) suspension (0.2 ml) was added to 1.8 ml of each sample and incubated at 37 
⁰ C for 30 min. Thereafter the samples were centrifuged at 3000 rpm for 10 min. The 
supernatant of each sample was then collected and analysed for haemoglobin released by UV 




suspension was added to 1.8 ml of PBS and distilled water, respectively, as a control. The 
degree of haemolysis was calculated using equation (4): 
Haemolysis (%) =   (
𝐀𝐁𝐒−𝐀𝐁𝐒𝟎
 𝐀𝐁𝐒𝟏𝟎𝟎−𝐀𝐁𝐒𝟎
) ×  𝟏𝟎𝟎 % (4) 
where ABS100 and ABS0 are the absorbances of the samples at 100% and 0% haemolysis, 
respectively. 
2.10 Stability studies 
The stability of VCM-GAPAH-LPHNPs was tested using DLS for 0,30,60 and 90 days of 
storage, at 4 °C and room temperature (51).  
2.11 In vitro antibacterial activity and fractional inhibitory concentration (FIC) index 
The minimum inhibitory concentration (MIC) values of bare VCM, GA, VCM-GAPAH-
LPHNPs and blank-GAPAH-LPHNPs were determined against SA and MRSA (pH 6 and 7.4) 
using the broth dilution method. Briefly, bacteria culture was grown in Nutrient Broth at 37°C 
in a shaking incubator (Labcon, USA) at 100 rpm for 18 h. Bacterial cultures were suitably 
diluted to achieve a concentration equivalent to 0.5 McFarland’s Standard using a DEN-1B 
McFarland densitometer (Latvia). This was again diluted to 1:150 with sterile distilled water 
to achieve colony forming units per ml (CFU/ml) of 5 × 105. All tested samples were serially 
diluted in MHB (pH 6 and 7.4) and incubated with the diluted bacterial cultures at 37°C in the 
shaking incubator at 100 rpm for a total of 96 h. At 24, 48 and 72 h, tested samples (5 µl) were 
spotted onto MHA and incubated at 37°C for 24 h. The bare drug formulation was used as the 
positive control while the blank formulation of LPHNPs was used as a negative control. All 
experiments were performed in triplicate (52-54). 
The antibacterial effect of bare VCM and GA in combination with VCM-GAPAH-LPHNPs 
against SA and MRSA was determined using the cumulative FIC of bare VCM and GA based 
on the Loewe additivity zero-interaction theory. The FIC index was calculated using equations 
5 and 6 and the FIC index is shown in (Table 1).  
 




FIC of agent A = 
𝐌𝐈𝐂 𝐨𝐟 𝐚𝐠𝐞𝐧𝐭 𝐀 𝐢𝐧 𝐜𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐚𝐠𝐞𝐧𝐭 𝐁
 𝐌𝐈𝐂 𝐨𝐟 𝐚𝐠𝐞𝐧𝐭 𝐀 𝐚𝐥𝐨𝐧𝐞
   (5) 
 
FIC of agent B = 
𝐌𝐈𝐂 𝐨𝐟 𝐚𝐠𝐞𝐧𝐭 𝐁 𝐢𝐧 𝐜𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐚𝐠𝐞𝐧𝐭 𝐀
 𝐌𝐈𝐂 𝐨𝐟 𝐚𝐠𝐞𝐧𝐭 𝐁 𝐚𝐥𝐨𝐧𝐞
    (6) 
Agent A: Bare VCM 
Agent B: GA 
Agents (A-B) in combination: VCM-GAPAH-LPHNPs 
 
Table 1. FIC index. 
FIC index Interpretation 
Σ FIC ≤ 0.5 Synergism 
> 0.5 Σ FIC ≤ 1 Additive 
> 1 Σ FIC < 2 Indifference 
Σ FIC ≥ 2 Antagonism 
 
Synergism combination indicates that a lower concentration of agents A and B is required in 
order to produce the same effect as agent A and agent B alone. While additive combination 
indicates that the same concentration of agents A and B are required in order to produce the 
same effect as agent A and agent B alone, the indifference combination indicates agent B is 
inactive since there was no effect of it to be added but only the effect of the active agent, which 
is agent A. However, antagonism combination indicates that higher concentration of agents A 
and B are required in order to produce the same effect as agent A and agent B alone (55-58).  
 
2.12 Time-killing assay 
The time-killing analysis of VCM-GAPAH-LPHNPs was conducted using the plate colony 
count method, as previously reported (59, 60). MRSA was cultured for 48 h at 37 °C in nutrient 




concentrations of 105 – 106 CFU/ml (61). Thereafter bare VCM, GA, sterile water and VCM-
GAPAH-LPHNPs were added to the PBS containing MRSA at a concentration of 5 times 
greater than MIC. The samples were placed in the shaking incubator at 37 °C. At 1, 2, 4, 8, 12 
and 24 h intervals, 0.1 ml of each sample was sub-cultured on nutrient agar plates for 24 h. The 
number of colonies counted were converted to log10 values and plotted on a graph. The 
experiment was performed in triplicate.  
2.13 MRSA biofilm reduction 
The eradication of MRSA biofilms by VCM-GAPAH-LPHNPs was determined using crystal 
violet (CV) assay (62). Briefly, 100 µl of MRSA suspensions (1.5 × 108 CFU/ml) in nutrient 
broth was inserted into a 96-well plate and incubated for 3 days at 37 °C to form a mature 
biofilm. Prior to treatment, the media was removed from the wells and the wells were 
thoroughly washed with PBS (pH 7.4) to remove non-adherent bacterial cells. Precisely, 
100 µl of bare VCM solution (390 µg/ml), GA solution (3,125 µg/ml) and VCM-GAPAH-
LPHNPs (390 µg/ml) formulation were added to the wells at a concentration of 100 times 
greater than MIC and incubated for 12 h at 37 °C. The wells were washed with PBS for the 
removal of the treatments and non-adherent bacterial cells. Thereafter, the wells were fixed 
with methanol for 15 mins. The plate was air-dried for 0.5 h, followed by the wells being 
stained with 0.1 % CV solution and kept in total darkness at room temperature (25 °C) for 20 
mins. After washing with distilled water, 30 % of acetic acid was added to each well. The 
absorbance per well was measured at λ 570 nm using equation (7) (Spectrostar Nano, 
Germany); all experiments were performed in triplicate. 
𝐏𝐞𝐫𝐜𝐞𝐧𝐭𝐚𝐠𝐞 𝐛𝐢𝐨𝐦𝐚𝐬𝐬 (%) = (
𝐀𝟓𝟕𝟎𝐧𝐦 𝐮𝐧𝐭𝐫𝐞𝐚𝐭𝐞𝐝 𝐜𝐞𝐥𝐥𝐬−𝐀𝟓𝟕𝟎𝐧𝐦 𝐭𝐫𝐞𝐚𝐭𝐞𝐝 𝐜𝐞𝐥𝐥𝐬 
𝐀𝟓𝟕𝟎𝐧𝐦 𝐮𝐧𝐭𝐫𝐞𝐚𝐭𝐞𝐝 𝐜𝐞𝐥𝐥𝐬 
) ×  𝟏𝟎𝟎   (7) 
3. Results and Discussion 
3.1 Structural Dynamics 
Molecular dynamics simulations were applied to three systems, i.e. components of the oil 
phase, water phase and both phases together for 500 ns to reveal the stability of the nanosystem 
using virtual conditions that mimic experimental conditions, expounding on the structural 
dynamics of each system.  
Root-mean-square deviation (RMSD) calculations confirmed that with both phases separately 
and together, all components of each system remained stably bound to each other, without 




as OA wraps around GA, while the water phase simulation showed the convergence of PAH, 
Tween 80 and VCM to form a complex where Tween 80 held the complex together. However, 
the components of the water phase merged with gaps in the complex, which were 
accommodated by OA and GA when all components of both phases were simulated together. 
Altogether, the oil and water phase together formed a stable complex that remained intact 
throughout the simulation.  
The stability and convergence of each system were confirmed by analyzing the RMSD during 
the simulation (Figure 1A). While the RMSD values of the oil phase system (black) remained 
with a 2 Å range, that of the water phase system (red) were much higher and went beyond a 12 
Å range with a deviation toward the end of the simulation. The combined oil and water phase 
system (green) corrected for these values as the system remained within a 2 Å range and did 
not have any extreme deviation throughout the simulation, although higher than the oil phase 
system owing to a larger complex size. In addition, the radii of gyration (RoG) of all three 
systems (Figure 1B) indicate that when the oil phase is combined with the water phase, the 
system becomes more compact than that of the water phase system alone, which correlates with 
the small size of the nanoparticles observed in section 3.1. These data are substantiated by 
results of hydrogen bond analysis (Figure 1C), which confirmed a greater number of hydrogen 
bonds in the complex with both phases combined (green), as opposed to either of the phases 
separately. This may have been a contributing factor to the compactness of the entire system. 
 
Figure 1. Post analyses of simulations of oil phase, water phase and both phases combined. 
Graph A. indicates RMSD analysis, B. RoG analysis and C. hydrogen bond analysis. 
Root-mean-square fluctuation (RMSF) analysis revealed energy fluctuations of each 
component of the 500 ns simulation of the combined oil and water phase. Figure 2 indicated 
that PAH fluctuated more than any other molecule in the simulation, while VCM and GA had 





Figure 2. RMSF analysis of 500 ns simulation of all components of the combined oil and 
water phase system. 
 
From these molecular dynamics analyses, it may be hypothesized that all five components of 
the oil and water phases bind stably and compactly to support the small size obtained from 
experimental data. Thus, this nanosystem has potential in the delivery of VCM to MRSA for 
the improvement of antibacterial activity. 
3.2 Preparation of VCM-GAPAH-LPHNPs 
VCM-GAPAH-LPHNPs were prepared using GA, PAH (polymer), OA (lipid), Tween 80 
(surfactant) and VCM hydrochloride by micro-dilution as previously reported (63). 
Preliminary studies were conducted using different ratios of lipid and polymer to obtain a 
formulation with optimum size, PDI and ZP according to pH 7.4, 6 and 4.5 conditions with 



















Table 2. Particle size, PDI and ZP of VCM-GAPAH-LPHNPs. 
PAH: OA (mg) pH Particle size (nm) PDI ZP (mV) EE % 
1:6 7.4 323.8 ± 0.5588 0.291 ± 0.007 - 7.4 ± 1.36  
 6 353.1 ± 9.824 0.728 ± 0.035 - 0.084 ± 0.035 38.60 ± 2.84 
 4.5 360.1 ± 2.967 0.288 ± 0.003 0.639 ± 0.484  
1:5 7.4 209.7 ± 1.244 0.277 ± 0.002 - 6.48 ± 0.25  
 6 280.1 ± 9.223 0.311 ± 0.0032 0. 169 ± 0.4 43.06 ± 0.55 
 4.5 280 ± 1.45 0.243 ± 0.01 0.708 ± 0.383  
1:4 7.4 198.4 ± 0.302 0.255 ± 0.003 - 3.8 ± 0.335  
 6 374.8 ± 5.435 0.279 ± 0.054 0.44 ± 0.325 69.46 ± 2.52 
 4.5 450.4 ± 1.33 0.377 ± 0.012 0.693 ± 0.44  
p value = 0.037      
 
At pH 7.4, as the polymer: lipid ratio decreased from 1:6 to 1:5, the particle size and PDI of 
the LPHNPs decreased from 323.8 nm to 209.7 nm and 0.29 to 0.27, respectively, whereas the 
ZP values changed from – 7.4 mV to – 6.48 mV, while the EE% improved from 38% to 43%. 
The increase in particle size relative to the increase in lipid content, may have resulted in an 
increased viscosity, thus causing the LPHNPs to swell (72). Alternatively, the lower polymer: 
lipid ratios formed more stable nanoparticles with homogenous size distributions and enhanced 
EE.  
The VCM-GAPAH-LPHNPs optimal formulation displayed size of 198.4 ± 0.302 nm, PDI of 
0.255 ± 0.003 and ZP of -3.8 ± 0.335 mV. In addition, the surface charge switched from 
negative at pH 7.4 (physiological pH) to positive at 6 (acidic pH). This may be due to the 
deprotonation of the carboxylic group (COOH) in OA, which may form an electrostatic bond 
with the primary amine groups of PAH, thereby neutralising the cationic effect (64). The 
positive charge of VCM-GAPAH-LPHNPs at acidic pH can be advantageous for the adhesion 
to the negatively charged bacterial membrane (65, 66).  
The VCM-GAPAH-LPHNPs EE% and DL% were found to be 69.46 ± 2.52% and 13.45 ± 
0.68%, respectively. This encapsulation was comparable to other VCM-loaded LPHNPs (28) 
and VCM-loaded nanoparticles (67, 68). Thus, enhanced entrapment efficiency may be due to 




(69). The results suggest that VCM-GAPAH-LPHNPs can effectively deliver drugs to acidic 
sites of infection and were further characterized.  
3.3 Characterization of optimal VCM-GAPAH-LPHNPs 
The TEM study of VCM-GAPAH-PNPs displayed a distinct circular shape with a size of 198 
nm, which corresponded with results of the DLS technique (Figure 3). To determine pH-
responsiveness, VCM-GAPAH-LPHNPs were placed in pH 7.4, 6 and 4.5 buffer solutions. As 
the pH changed from 7.4 to 6 and then to 4.5, the size of VCM-GAPAH-LPHNPs increased 
from 198.4 nm to 374.8 nm to 450.4 nm, the PDI increased from 0.255 to 0.279 to 0.377 and 
the ZP switched from -3.8 mV to 0.44 mV to 0.693 mV.  
At pH 7.4 conditions, LPHNPs were negatively charged due to the presence of OA on the 
LPHNPs matrix. At low pH values, the amine group and carboxylic group remained 
protonated, resulting in cleavage of the ionic bonds between PAH and OA and this was 
displayed by the positive ZP at acidic pH conditions (70). The cleavage of ionic bonds 
decreased the affinity between the polymer and lipid resulting in the deconstruction of LPHNPs 
dispersion, thus causing an increase in their particle size. The size change observed relates to 
the structural transformation of LPHNPs and the negative to positive charge switching was 
predicted to positively affect the drug release and promote binding to the negatively (anionic) 
charged bacterial cell wall, thus improving antibacterial activity (69).  
 





3.4 Thermal profiles of VCM-GAPAH-LPHNPs  
Thermal analysis was performed to investigate the thermal behaviour of the components of 
LPHNPs. The thermal profiles of the bare VCM, PAH, GA, physical composition and 
lyophilized VCM-GAPAH-LPHNPs were compared (Figure 4). VCM, PAH and GA peaks of 
were observed at 103.40 °C, 262.99 °C and 265.72 °C, respectively. The physical mixture 
demonstrated similar behaviour to the individual materials. The lyophilized VCM-GAPAH-
LPHNPs formulation showed the disappearance of the VCM thermal peak, confirming the 
transformation from crystallization into its amorphous form, as it was encapsulated within the 
LPHNPs matrix (71).  
 
Figure 4. DSC thermogram of (A) VCM (B) PAH (C) GA (D) physical composition of 
VCM, PAH and GA (E) lyophilized VCM-GAPAH-LPHNPs. 
3.5 In vitro drug release of VCM-GAPAH-LPHNPs 
The in vitro release profile of pH-responsive VCM/GA loaded LPHNPs was investigated using 
the dialysis bag method at pH 7.4 and pH 6. Compared to the release of bare VCM, the release 
of VCM-GAPAH-LPHNPs was slower, indicating controlled release (Figure 5). The controlled 
release of VCM-GAPAH-LPHNPs could be attributed to the lipid-polymer matrix of VCM-
GAPAH-LPHNPs, which entrap the drug for a more extended period (72). In addition, the long 




VCM, resulting in slower drug release (73), which is advantageous for extended and sustained 
antibacterial activity (74). 
From the 1st hour, VCM-GAPAH-LPHNPs illustrated a significantly faster release (p < 0.05) 
at pH 6 than at pH 7.4 (Figure 6), for up to 48 h. An elevated release at acidic pH occurred due 
to the protonation of OA and PAH at acidic pH, which resulted in the cleavage of the ion pair 
bond and an increase in the size of nanoparticles due to electrostatic repulsion between PAH 
and OA. This resulted in the swelling of LPHNPs, causing them to burst leading to an enhanced 
and faster VCM release (75, 76). This pH-sensitive release activity is crucial for enhanced 
VCM protection at pH 7.4, enhanced drug release and bioavailability at the acidic infection 
sites, thus enhancing antibacterial activity (75, 77).  
 





Figure 6. Effect of pH on drug release profiles of VCM-GAPAH-LPHNPs (n=3). 
 
 
Regarding kinetic analysis, optimized VCM-GAPAH-LPHNPs were input into zero-order, 
first-order, Higuchi, Hixson-Crowell, Korsmeyer-Peppas and Weibull models (Table 3). 
Although the release of the VCM-GAPAH-LPHNPs was higher at pH 6, it had similar kinetic 
behaviour to the release at pH 7.4. The highest R2 values were 0.945 and 0.991, while the 
lowest RMSE values were 4.853 and 2.189 at pH 7.4 and pH 6, respectively. Thus, the Weibull 
model was considered the best fit model for VCM-GAPAH-LPHNPs release at pH 7.4 and pH 
6. 
The Weibull release exponent (β) value is used to determine the drug release mechanism, with 
β ≤ 0.75 indicating a Fickian diffusion and 0.75 < β < 1 indicating a combined mechanism, 
whereas a β > 1 is associated with a collapse release mechanism. The β values for VCM-
GAPAH-LPHNPs were 0.553 and 0.741 at pH 7.4 and pH 6, respectively, indicating Fickian 
diffusion as the release mechanism. 
The Korsmeyer-Peppas release exponent (n) value is also used to determine the drug release 
mechanism, with n ≤ 0.43 indicating a Fickian diffusion, 0.43 < n < 0.85 indicating a 
combination of diffusion and erosion, whereas n ≥ 0.85 suggests an erosion release mechanism. 




model, whereas (n) values were 0.414 and 0.351 at pH 7.4 and pH 6 respectively, confirming 
the Fickian diffusion mechanism of VCM release from the VCM-GAPAH-LPHNPs (78, 79). 
 
Table 3. Drug release kinetics data for VCM-GAPAH-LPHNPs. 
Model      R2     RMSE  Release exponent  
pH 7.4 6 7.4   6 7.4     6 
Zero order 0.028 -0.764 20.578 30.870 - - 
First order 0.746 0.895 10.470 7.069 - - 
Higuchi 0.867 0.745 22.754 11.325 - - 
Hixson-Crowell 0.614 0.735 19.4 11.224 - - 
Korsmeyer-Peppas 0.893 0.945 6.8 5.582 0.414 0.351 
Weibull 0.945 0.991 4.853 2.189 0.553 0.741 
 
 
3.6 In vitro cytotoxicity  
A cytotoxicity study was conducted to determine the biosafety of the formulation. The 
cytotoxicity of VCM-GAPAH-LPHNPs was determined using the MTT assay, performed on 
CACO-2 and HepG2 cells. The results showed that VCM-GAPAH-LPHNPs maintained over 
75% cell viability across concentrations of 20-80 µg/ml after 24 h, indicating non-cytotoxicity 
(80) (Figure 7). The results from the MTT assay using VCM-GAPAH-LPHNPs indicated a 
high percentage of cell viability and dose-dependent trends for all cell lines. Since VCM-
GAPAH-LPHNPs showed no significant cytotoxic effect on any of the cell lines, it is thus safe 





Figure 7. MTT assay of VCM-GAPAH-LPHNPs. 
 
3.7 Haemolysis 
Haemolysis of RBCs due to lipid-polymer hybrid systems may be detrimental; therefore, it is 
important to evaluate the safety of formulation. Haemolytic properties of VCM-GAPAH-
LPHNPs were evaluated on sheep RBCs (Figure 8). VCM-GAPAH-LPHNPs were found to be 
non-haemolytic to RBCs in the concentration range tested (0.05 to 0.5 mg/ml). At 0.5 mg/ml, 







Figure 8. Haemolysis assay of VCM-GAPAH-LPHNPs. 
 
3.8 Stability studies 
The experimental results show no significant changes in particle size, PDI and ZP of VCM-
GAPAH-LPHNPs throughout the 90 days of storage, at 4 °C and at room temperature – the 
system remained stable (Table 4). 
 




4 °C Room temperature (25 °C) 








0 198.4 ± 0.302 0.255 ± 0.003 -3.8 ± 0.335 198.4 ± 0.302 0.255 ± 0.003 -3.8 ± 0.335 
30 198.5 ± 0.402 0.155 ± 0.002 -3.63 ± 0.88 200.5 ± 1.124 0.257 ± 0.004 -1.17 ± 0.02 
60 199 ± 0.452 0.251 ± 0.041 -2.8 ± 0.55 205.2 ± 8.25 0.38 ± 0.028 -4.18 ± 2.26 
90 199.9 ± 0.40 0.26 ± 0.005 -2.82 ± 0.35 206.4 ± 3.2 0.46 ± 1.33 -5.1 ± 3.14 
 
 
3.9 In vitro antibacterial activity and FIC index 
The micro broth dilution method was used to determine the MIC of VCM-GAPAH-LPHNPs 
at pH 7.4 and 6 against SA and MRSA (Table 5). The MIC values for bare VCM against SA 
and MRSA at pH 7.4 was 1.95 µg/ml and 3.9 µg/ml, respectively and increased to 3.9 µg/ml 
and 7.8 µg/ml, respectively, at pH 6. 
The MIC values of VCM-GAPAH-LPHNPs against SA and MRSA at pH 7.4 was 7.8 µg/ml 




GAPAH-LPHNPs had improved and sustained antibacterial activity compared to bare VCM 
activity against MRSA only at both pH levels. The enhanced extended antibacterial activity of 
VCM-GAPAH-LPHNPs, in comparison to the bare VCM, could be attributed to its subcellular 
size with a large surface area and the presence of GA acid for its known antibacterial properties 
(81, 82). Additionally, the lipophilic nature of VCM-GAPAH-LPHNPs could allow for 
enhanced uptake into the bacterial cell wall, thus enhancing VCM activity (83). Furthermore, 
the presence of OA could have enhanced VCM-GAPAH-LPHNPs activity (84). 
On the other hand, at pH 7.4, GA activity against SA and MRSA was extended up to 48 h and 
72 h respectively, while at pH 6, GA had activity for only 24 h against SA and MRSA. More 
importantly, VCM-GAPAH-LPHNPs demonstrated lower MIC values against MRSA at pH 6 
than pH 7.4. At 24 h, VCM-GAPAH-LPHNPs activity was 8 times greater against MRSA at 
pH 6 than at pH 7.4, while at 48 h and 72 h, VCM-GAPAH-LPHNPs was 4 times greater 
against MRSA at pH 6 than at pH 7.4. At 96 h, VCM-GAPAH-LPHNPs was 2 times greater 
against MRSA at pH 6 compared to pH 7.4. 
The enhanced antibacterial activity of VCM-GAPAH-LPHNPs against MRSA at acidic pH 
conditions may be due to VCM-GAPAH-LPHNPs protonation and cleavage of ionic bonds 
between PAH and OA, thus resulting in an enhanced VCM release. Furthermore, VCM-
GAPAH-LPHNPs charge switching to positive in acidic conditions can enhance the binding of 
VCM-GAPAH-LPHNPs with the negatively charged bacterial cell wall, leading to a higher 
release and localization of VCM at acidic infection sites, thereby increasing its uptake into the 
bacterial cell wall (85, 86). 
The formation of ion pairs between OA and PAH could have enhanced the diffusion of VCM 
and GA across the thicker peptidoglycan layer of MRSA compared to SA (87). In addition, the 
enhanced penetration of VCM and GA, along with OA into the lipophilic bacterial cell 
membrane could have contributed to the enhanced antibacterial activity of MRSA compared 






Table 5. In vitro antibacterial activity at pH 7.4 and pH 6. 
 SA MRSA 
Time (h) 24 48 72 96 24 48 72 96 
 
In vitro antibacterial activity at pH 7.4 
Bare VCM 1.95 3.9 3.9 7.8 3.9 7.8 15.6 15.6 
VCM-GAPAH-LPHNPs 7.8 3.9 3.9 7.8 3.9 3.9 3.9 7.8 
GA 125 125 NA NA 31.25 62.5 62.5 NA 
Blank GAPAH-LPHNPs NA NA NA NA NA NA NA NA 
 
In vitro antibacterial activity at pH 6 
Bare VCM 3.9 3.9 7.8 15.6 7.8 15.6 15.6 31.25 
VCM-GAPAH-LPHNPs 3.9 3.9 7.8 7.8 0.48 0.97 0.97 3.9 
GA 125 NA NA NA 31.25 NA NA NA 
Blank GAPAH-LPHNPs NA NA NA NA NA NA NA NA 
NA = No activity. The values are expressed as mean (n=3). 
 
FIC index was calculated using equations 5 and 6, to determine the combined impact of VCM 
and GA against SA and MRSA at pH 7.4 and 6 (Table 6). For 24, 48, 72 and 96 h against SA 
at pH 7.4, Σ FIC was 4.062, 1.031, 1 and 1, respectively, indicating antagonistic, indifferent 
and additive combinations, respectively. Whereas at pH 6, Σ FIC was 1.031, 1, 1 and 0.5 
respectively, indicating indifferent, additive and synergistic combinations, respectively.  
Furthermore, at pH 7.4, Σ FIC against MRSA was 1.124, 0.562, 0.312 and 0.5 respectively, 
indicating indifferent, additive and synergistic combinations, respectively. Lastly, Σ FIC 
against MRSA at pH 6, was 0.076, 0.062, 0.062 and 0.012 respectively, indicating synergistic 
combinations at all time intervals. 
Synergy indicates that a lower concentration of VCM-GAPAH-LPHNPs is required in order 
to produce the same effect as VCM and GA alone. Synergistic interactions can potentially 
increase antibacterial efficacy and decrease toxicity. Whereas additivity indicates that the same 
concentration of VCM-GAPAH-LPHNPs is required in order to produce the same effect as 
VCM and GA alone. However, indifference is when one compound, which is GA, is inactive 
because there was no effect of it to be added but only the effect of the active drug, which was 
VCM. Lastly, antagonism indicates that a higher concentration of VCM-GAPAH-LPHNPs is 




interactions can potentially decrease antibacterial efficacy and increase toxicity (55-58). 
Significantly, VCM-GAPAH-LPHNPs works best against MRSA at pH 6, confirming that GA 
and VCM had a synergistic effect at the acidic conditions. 
VCM hinders bacterial cell wall synthesis by binding to the D-alanyl-D-alanine moiety of the 
growing peptide chain (89), whereas GA hinders bacterial cell membrane synthesis via the 
inhibition of genes involved in carbohydrate, amino acid and nucleic acid metabolism (35, 90). 
Moreover, studies have shown that GA inhibits bacterial DNA replication which could result 
in the inhibition of the production of bacterial toxins and enzymes (91). GA also has the ability 
to regulate the production of haemolysins, leukotoxins and adhesins (92, 93). Long et al. (2013) 
reported a decrease in the expression of saeR, hla, mecA and sbi genes after SA incubation 
with GA (94). In addition, Li et al. (2012) reported the downregulation of RNAIII transcript 
after MRSA incubation with GA (95). Hence GA can modulate virulence by synergistically 
inducing antibacterial effects. However, the precise mechanism underlying its activity remains 
unknown (94, 95). 
On the other hand, the administration and exposure of VCM to human cells has several harmful 
effects such as nephrotoxicity, neutropenia and ototoxicity (96). However, GA can cause 
alkalosis, muscular paralysis and hyperkalaemia (97). By co-encapsulating VCM and GA 
within LPHNPs, their pharmacokinetic profiles and therapeutic indices are remarkably 
enhanced (98). Therefore, the synergistic combination of VCM and GA against MRSA at 
acidic pH can potentially increase the antibacterial efficacy, reduce cytotoxicity and prevent 













Table 6. FIC index against SA and MRSA at pH 7.4 and 6. 
SA (pH 7.4) 
Time (h) Bare VCM GA Σ FIC (Bare VCM + GA) Interpretation 
24 4 0.062 4.062 Antagonism 
48 1 0.031 1.031 Indifference 
72 1 - 1 Additive 
96 1 - 1 Additive 
SA (pH 6) 
24 1 0.031 1.031 Indifference 
48 1 - 1 Additive 
72 1 - 1 Additive 
96 0.5 - 0.5 Synergy 
            MRSA (pH 7.4)   
24 1 0.124 1.124 Indifference 
48 0.5 0.062 0.562 Additive 
72 0.25 0.062 0.312 Synergy 
96 0.5 - 0.5 Synergy 
                MRSA (pH 6)   
24 0.061 0.015 0.076 Synergy 
48 0.062 - 0.062 Synergy 
72 0.062 - 0.062 Synergy 
96 0.012 - 0.012 Synergy 
 
3.10 Time-killing assay  
Time-kill analysis results of bare VCM, GA, control and VCM-GAPAH-LPHNPs at 5 times 
greater MIC against MRSA are illustrated in Figure 9. At 8 h interval GA eliminated 26% of 
bacteria, bare VCM eliminated 55% of bacteria and ultimately, VCM-GAPAH-LPHNPs 
eliminated 68% of bacteria. VCM-GAPAH-LPHNPs displayed spontaneous bacterial 
elimination with nearly 75% clearance of MRSA in <12 h with an equal concentration of bare 
VCM. At 12 h VCM-GAPAH-LPHNPs demonstrated 100% bacterial elimination, whereas 
bare VCM demonstrated 66% bacterial elimination. Hence VCM-GAPAH-LPHNPs could 





Figure 9. The killing kinetics of MRSA exposed to 5x MIC of bare VCM, VCM-GAPAH-
LPHNPs, GA and sterile water (control). 
 
3.11 MRSA biofilm elimination 
The CV assay was performed to analyse the ability of VCM-GAPAH-LPHNPs to decrease 
MRSA biofilms by calculating the biomass percentage (Figure 10). The control (untreated 
biofilms) demonstrated high purple intensity (Figure 11A) resulting in a high percentage 
biomass of 100 %. The percentage biomass of GA, bare VCM and VCM-GAPAH-LPHNPs 
present were 95 %, 74 % and 31 %, respectively. Hence GA, bare VCM and VCM-GAPAH-
LPHNPs eliminated 5 %, 26 % and 69 % of MRSA biofilms, respectively.  
Bare VCM demonstrated a reduced purple intensity (Figure 11B), indicating a lower 
percentage of MRSA biomass, compared to the control. Hence a decrease in biofilms was 
observed when treated with bare VCM, demonstrating its considerable antibacterial ability. 
Notably, GA treated biofilms exhibited higher purple intensity (Figure 11C) than VCM treated 
biofilms, which indicated a higher percentage of MRSA biomass. 
Interestingly, a substantial decrease in biofilms treated with VCM-GAPAH-LPHNPs 
formulation was observed, as shown in the reduction of purple intensity (Figure 11D), when 
compared to all other treated and untreated samples. This confirms the superior potential of 





Figure 10. Percentage biomass of MRSA exposed to 100x MIC of control (untreated 
biofilms), GA, bare VCM and VCM-GAPAH-LPHNPs. 
 
 
Figure 11. Crystal violet assay of A) MRSA untreated biofilms; B) MRSA biofilms treated 









There has been an increasing interest in the development of novel nanoantibiotic drug delivery 
systems due to the global health threat posed by antimicrobial resistance. In this study, the 
potential to prepare novel pH-responsive lipid-polymer hybrid nanoparticles with co-loaded 
GA and VCM (VCM-GAPAH-LPHNPs) was explored. A stable VCM-GAPAH-LPHNPs 
formulation was successfully prepared with favourable particle size, PDI, ZP, morphology, 
EE% and DL%. The stability of the nanosystems were demonstrated via the analyses of in 
silico studies. In vitro biocompatibility and haemolytic studies confirmed the biosafety of 
VCM-GAPAH-LPHNPs. The release of VCM from VCM-GAPAH-LPHNPs was higher at pH 
6 compared to physiological pH 7.4. The in vitro antibacterial studies of the VCM-GAPAH-
LPHNPs against MRSA revealed an enhanced antibacterial effect at acidic medium compared 
to pH 7.4, with 75% bacterial elimination in <12 h. The crystal violet assay further validated 
the antibacterial potential of VCM-GAPAH-LPHNPs by displaying a significantly higher 
percentage of biofilm eradication when compared to bare VCM, GA and untreated biofilms. 
Our findings suggest that novel VCM-GAPAH-LPHNPS can potentially be effective in drug 
delivery to the target site of bacterial infection with low pH and effectively prevent the 
progression of antimicrobial resistance. In addition, the proposed nanosystem can be used to 
co-deliver GA with other antimicrobial agents to further explore the antimicrobial potential 
against other species of bacteria and microorganisms. 
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Chapter Four – General conclusions and future recommendations 
4.1 Introduction 
 
Globally, infectious diseases are one of the top ten leading causes of death. The discovery of 
antibiotics greatly improved the prevention and control of infections, however, the 
disadvantages and overuse of conventional antibiotics led to the development of therapy 
complications and the antimicrobial resistance crisis. One of the major health risks is MRSA 
infection, which has increased mortality and morbidity rates worldwide. VCM is the last 
effective resort against MRSA, with the spread of resistance being a serious concern, urging 
the need to develop strategies to restore VCM efficiency. Although novel nano drug delivery 
systems have shown enhanced VCM therapy, there is still a need to optimize nano antibiotic 
carriers to protect and localize VCM during systemic circulation, target VCM release and 
improve its bioavailability at the infection site. Therefore, current research advances focus on 
developing pH-responsive nanosystems to improve VCM targeted delivery to the acidic 
infection sites. LPHNPs are an efficient nanosystem for antibiotic delivery and enhancing 
antibacterial activity. As per the study aim, the results of the objectives outlined the potential 
of novel pH-responsive lipid-polymer hybrid nanoparticles co-delivery with VCM and GA to 
enhance its antibacterial efficacy.  
The results pertaining to the study aim and objectives were as follows:  
1. To formulate and optimize novel pH-responsive GAPAH lipid-polymer hybrid nanoparticles 
encapsulating VCM and GA.  
2. To optimize and characterize VCM-GAPAH-LPHNPs in terms of particle size, PDI, ZP, 
pH-responsiveness, morphology, entrapment efficiency and in vitro drug release. 
3. To assess in vitro antibacterial activity of VCM-GAPAH-LPHNPs against MRSA. 
4. To identify time-killing kinetics of VCM-GAPAH-LPHNPs against MRSA. 
5. To evaluate antibiofilm activity of the novel VCM-GAPAH-LPHNPs. 
The main conclusions generated from the research data are summarized below: 
• VCM-loaded GA and polyallylamine hydrochloride lipid-polymer hybrid nanoparticles 




• The cytotoxicity studies performed by MTT assay on mammalian cell lines (CACO-2 
and HEPG2) revealed that VCM-GAPAH-LPHNPs was a biologically safe 
formulation.   
• Spherically shaped VCM-GAPAH-LPHNPs were successfully prepared using micro-
emulsion technique. The optimal formulation showed pH-responsiveness in terms of 
size, PDI and ZP. VCM-GAPAH-LPHNPs size increased from 198.4 ± 0.302 nm at pH 
7.4 to 374.8 ± 5.435 nm at pH 6  and 450.4 ± 1.33 nm at pH 4.5,  respectively. PDI 
increased from 0.255 ± 0.003 at pH 7.4 to 0.279 ± 0.054 at pH 6 and 0.377 ± 0.012 at 
pH 4.5, respectively. Also, ZP switched from – 3.8 ± 0.335 mV at pH 7.4 to + 0.44 ± 
0.325 mV at pH 6 and + 0.693 ± 0.44 mV at pH 4.5, respectively. The EE % was found 
to be 69.46 ± 2.52.  
• In vitro drug release studies showed a controlled and pH-dependent VCM release over 
a period of 48 hours. VCM-GAPAH-LPHNPs had faster drug release at pH 6 compared 
to pH 7.4. 
• In vitro antibacterial activity against SA and MRSA confirmed the superiority of VCM-
GAPAH-LPHNPs over bare VCM, GA and blank-LPHNPs as  VCM-GAPAH-
LPHNPs had enhanced and prolonged activity against MRSA at pH 6 and pH 7.4. 
Moreover, VCM-GAPAH-LPHNPs activity was eight times better against MRSA at 
pH 6 than at pH 7.4.  
• The time-killing assay study showed that VCM-GAPAH-LPHNPs could effectively 
treat MRSA infections by showing 75% bacterial cell death in less than 12 hours. 
• VCM-GAPAH-LPHNPs showed a decrease in crystal violet intensity and were able to 
eradicate 69 % of MRSA biofilms.  
• The findings of this study, therefore, confirmed the potential of the novel GA and 
polyallylamine hydrochloride for preparation of pH-responsive LPHNPs for enhancing 
VCM efficacy. In  addition, these  findings can serve as a basis for future scientific 
research on the synthesis of novel natural compounds to develop pH-responsive 





4.2 Significance of the findings in the study 
The pH-responsive VCM-GAPAH-LPHNPs were designed to improve VCM targeted delivery 
to acidic target sites of infection for enhancing antibacterial activity. The significance of the 
findings of the study are as follows: 
New Pharmaceutical Products 
Novel pH-responsive VCM-GAPAH-LPHNPs formulation were successfully developed in this 
study,  which can stimulate the pharmaceutical industry to develop new pH-responsive 
materials and medicines to improve antibiotic delivery.  
Improved patient therapy and disease treatment 
The in vitro studies of the developed pH-responsive nanosystem showed enhanced antibiotic 
activity and sustained VCM release in acidic medium. This nanosystem has the potential to 
improve bacterial infection therapy by protecting the antibiotic during systemic circulation, 
target the delivery of optimal antibiotic concentration to infection sites, decrease healthy sites 
exposure to the antibiotic and enhance bacterial antibiotic uptake. These benefits can result in 
reducing antibiotic dosing frequency, adverse drug reactions and toxicity. This can lead to 
improving patient compliance, enhancing antibacterial therapy and combating antimicrobial 
resistance threats. 
Creation of new scientific knowledge 
This study can identify new scientific advancements in the preparation and characterization of 
combinational delivery of antibiotics and natural plant compounds of pH-responsive lipid-
polymer hybrid nanoparticles. This can serve as a basis for smart nano delivery systems 
development and enhance their potential pharmaceutical applications.  
 
Stimulation of new research 
The findings can provide potential research advancements to explore the pH-responsive natural 
compounds i.e., GA, for potential applications in pH-responsive LPHNPs for the co-delivery 
of antibiotics and natural compounds nanosystems formulation for various drug classes, such 




4.3  Recommendations for future studies 
The present study concluded that the synthesis of novel pH-responsive GA and polyallylamine 
hydrochloride formulation for VCM and GA targeted co-delivery can enhance treatment of 
bacterial infections. The following studies are recommended to improve drug targeted delivery 
via pH-responsive VCM-LPHNPs:  
• Other natural compounds, lipids and polymers can be investigated to analyze the effect 
of lipid-polymer type and ratios on pH-responsiveness, drug entrapment, drug release 
and antibacterial activity.  
• Additional in vitro and in vivo antimicrobial activity screening against other Gram-
positive and Gram-negative bacteria should be done to further assess VCM-GAPAH-
LPHNPs spectrum of activity.  
• Further in silico modeling and simulation studies are required to better understand 
molecular interactions of VCM-GAPAH-LPHNPs against SA and MRSA bacteria. 
• In vivo pharmacokinetic profiling could be conducted to provide more information 
regarding pH-responsive targeted drug delivery, bioavailability and bio-distribution 
profiles.  
• A large-scale production method could be established to influence the development and 
optimization of the nano antibiotic formulation by local pharmaceutical industries.  
 
4.4 Conclusion 
The findings of this study confirmed the potential of the synthesized novel pH-responsive 
nanoformulation in targeting antibiotic delivery to improve bacterial infection therapy. This 
study has contributed to the advancement of drug delivery strategies to address the limitations 
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